























CRITICAL ROLE OF 
ANGIOPOIETIN PATHWAY IN  
ISCHEMIA-REPERFUSION 







	   	  
 3 
	  
CRITICAL	  ROLE	  OF	  ANGIOPOIETIN	  PATHWAY	  IN	  
ISCHEMIA-­‐REPERFUSION	  INJURY	  














Cardiopulmonary	  Research	  Group,	  
Transplantation	  Laboratory,	  Haartman	  Institute,	  














To	  be	  publicly	  discussed	  with	  the	  permission	  of	  the	  Faculty	  of	  
Medicine,	  University	  of	  Helsinki,	  in	  Lecture	  Hall	  3,	  Meilahti	  Hospital,	  








Professor	  Karl	  Lemström,	  MD,	  PhD	  
Cardiopulmonary	  Research	  Group,	  
Transplantation	  Laboratory,	  Haartman	  Institute,	  







Professor	  Timo	  Paavonen,	  
Department	  of	  Pathology,	  School	  of	  Medicine,	  





Professor	  Hannu	  Sariola,	  
Developmental	  Biology,	  Institute	  of	  Biomedicine	  








Professor	  Daniel	  Goldstein,	  
Yale	  Cardiovascular	  Research	  Center,	  School	  of	  Medicine,	  
Yale	  University,	  
New	  Haven,	  CT,	  USA	  
	  


















































Author	  contact	  information:	  
Transplantation	  Laboratory,	  Haartman	  Institute	  
P.O.	  Box	  21	  (Haartmaninkatu	  3)	  
FI-­‐00014	  University	  of	  Helsinki,	  Helsinki,	  Finland	  
Tel:	  +358-­‐9-­‐19126582	  
Fax:	  +358-­‐9-­‐2411227	  
E-­‐mail:	  simo.syrjala@helsinki.fi	   	  
 7 
TABLE	  OF	  CONTENTS	  
ORIGINAL	  PUBLICATIONS	  ............................................................	  9	  
ABBREVIATIONS	  ........................................................................	  10	  
ABSTRACT	  .................................................................................	  12	  
INTRODUCTION	  .........................................................................	  15	  
REVIEW	  OF	  THE	  LITERATURE	  .....................................................	  16	  
1.	  Clinical	  heart	  transplantation	  .............................................	  16	  
1.1.	  Background	  ......................................................................	  16	  
1.2.	  General	  histology	  of	  the	  heart	  ........................................	  17	  
1.3.	  Indications,	  patient	  characteristics,	  and	  outcome	  ..........	  18	  
1.4.	  Risk	  factors	  ......................................................................	  20	  
2.	  Ischemia-­‐reperfusion	  injury	  ...............................................	  23	  
2.1.	  Ischemia	  and	  hypothermia	  ..............................................	  23	  
2.2.	  Reperfusion	  and	  re-­‐oxygenation	  .....................................	  24	  
2.3.	  Microvascular	  dysfunction	  ..............................................	  26	  
3.	  Immunobiology	  ..................................................................	  28	  
3.1.	  Innate	  immune	  system	  ....................................................	  28	  
3.2.	  Alloimmune	  system	  .........................................................	  31	  
3.5.	  Acute	  rejection	  ................................................................	  36	  
3.6.	  Immunosuppression	  ........................................................	  38	  
3.7.	  Chronic	  rejection	  .............................................................	  40	  
4.	  Angiopoietin	  pathway	  ........................................................	  44	  
4.1.	  General	  ............................................................................	  44	  
4.2.	  Angiopoietin-­‐1	  .................................................................	  45	  
4.3.	  Angiopoietin-­‐2	  .................................................................	  47	  
AIMS	  OF	  THE	  STUDY	  ..................................................................	  49	  
METHODS	  .................................................................................	  50	  
1.	  Experimental	  rat	  cardiac	  transplantation	  model	  ................	  50	  
2.	  Transmission	  electron	  microscopy	  analysis	  .......................	  51	  
3.	  Immunohistochemistry	  and	  immunofluorescence	  	  
	  	  	  	  stainings	  ..............................................................................	  52	  
 8 
4.	  Histological	  evaluation	  .......................................................	  53	  
5.	  Enzyme-­‐linked	  immunosorbent	  assay	  ................................	  53	  
6.	  Cell	  culture	  assays	  ..............................................................	  54	  
7.	  Microvascular	  leakage	  and	  perfusion	  assay	  .......................	  54	  
8.	  Gene	  expression	  analysis	  ...................................................	  55	  
9.	  Heart	  transplant	  patients	  ...................................................	  56	  
10.	  Statistical	  analysis	  .............................................................	  56	  
RESULTS	  ....................................................................................	  57	  
1.	  Prolonged	  ischemic	  preservation	  promoted	  ischemia-­‐	  
	  	  	  	  reperfusion	  injury-­‐mediated	  myocardial	  injury	  and	  	  	  	  
	  	  	  	  inflammation	  in	  rat	  cardiac	  allografts	  (I)	  ............................	  57	  
2.	  Prolonged	  ischemic	  preservation	  enhanced	  chronic	  	  
	  	  	  	  rejection	  (I)	  .........................................................................	  57	  
3.	  Hypoxia	  induced	  endothelial	  cells	  to	  release	  Ang2	  ............	  58	  
4.	  Cardiac	  transplantation	  induces	  immediate	  changes	  
	  	  	  	  in	  angiogenic	  growth	  factor	  expression	  in	  human	  and	  
	  	  	  	  in	  rat	  (III)	  .............................................................................	  61	  
5.	  Targeting	  Ang/Tie2	  pathway	  prevented	  Tie2-­‐dependent	  	  	  	  	  	  
	  	  	  	  endothelial	  destabilization	  and	  microvascular	  
	  	  	  	  dysfunction	  induced	  by	  ischemic	  preservation	  (II-­‐III)	  .........	  62	  
6.	  Acute	  rejection	  can	  be	  restrained	  by	  endothelial	  	  
	  	  	  	  inactivation	  (III)	  ...................................................................	  64	  
7.	  Cardiac	  allograft	  vasculopathy	  development	  is	  
	  	  	  	  correlated	  with	  preoperative	  ischemia	  time	  and	  the	  
	  	  	  	  number	  of	  endothelial	  cells	  and	  pericytes	  (I-­‐III)	  .................	  65	  
DISCUSSION	  ..............................................................................	  69	  
YHTEENVETO	  .............................................................................	  81	  
ACKNOWLEDGMENTS	  ...............................................................	  84	  





The	  thesis	  is	  based	  on	  the	  following	  original	  publications	  referred	  to	  
in	  the	  text	  by	  their	  Roman	  numerals:	  
 
I	  Syrjälä	  SO,	  Keränen	  MA,	  Tuuminen	  R,	  Nykänen	  AI,	  Krebs	  R,	  
Lemström	  KB:	  Increased	  Th17	  rather	  than	  Th1	  alloimmune	  response	  
is	  associated	  with	  cardiac	  allograft	  vasculopathy	  after	  hypothermic	  
preservation	  in	  the	  rat.	  J	  Heart	  Lung	  Transplant.	  2010	  29(9):1047-­‐
1057.	  
	  
II	  Syrjälä	  SO,	  Nykänen	  AI,	  Tuuminen	  R	  Raissadati	  A,	  Keränen	  MAI,	  
Arnaudova	  R,	  Krebs	  R,	  Koh	  GY,	  Alitalo	  K,	  Lemström	  KB:	  Donor	  Heart	  
Treatment	  with	  COMP-­‐Ang1	  Limits	  Ischemia-­‐Reperfusion	  Injury	  and	  
Chronic	  Rejection	  of	  Cardiac	  Allografts.	  SUBMITTED.	  
	  
III	  Syrjälä	  SO,	  Tuuminen	  R,	  Nykänen	  AI,	  Raissadati	  A,	  Dashkevich	  A,	  
Keränen	  MAI,	  Arnaudova	  R,	  Krebs	  R,	  Leow	  CC,	  Saharinen	  P,	  Alitalo	  K,	  
Lemström	  KB:	  Angiopoietin-­‐2	  Inhibition	  Prevents	  Transplant	  
Ischemia-­‐	  Reperfusion	  Injury	  and	  Chronic	  Rejection	  in	  Rat	  Cardiac	  
Allografts.	  Am	  J	  Transplant.	  2014	  14(5):1096–108.	  




AMR	   	   antibody-­‐mediated	  rejection	  
Ang	   	   angiopoietin	  
AP-­‐1	   	   activation	  protein	  1	  
APC	   	   antigen-­‐presenting	  cell	  
CCL21	   	   chemokine	  (C-­‐C	  motif)	  ligand	  21	  
CCR7	   	   C-­‐C	  chemokine	  receptor	  type	  7	  
CD	   	   cluster	  of	  differentiation	  
CMC	   	   cardiomyocyte	  
CMV	   	   cytomegalovirus	  
COMP	   	   cartilage	  oligomeric	  matrix	  protein	  
COX	   	   cyclooxygenase	  
CTL	   	   cytotoxic	  lymphocyte	  
DA	   	   Dark	  Agouti	  rat	  
DAMP	   	   danger/damage-­‐associated	  molecular	  pattern	  
DNA	   	   deoxyribonucleic	  acid	  
DC	   	   dendritic	  cell	  
EC	   	   endothelial	  cell	  
ECM	   	   extracellular	  matrix	  
ELISA	   	   enzyme-­‐linked	  immunosorbent	  assay	  
ET-­‐1	   	   endothelin-­‐1	  
FITC	   	   fluorescein	  isothiocyanate	  
FOXP3	   	   forkhead	  box	  p3	  
HAS	   	   hyaluronic	  acid	  synthase	  
HIF-­‐1	   	   hypoxia-­‐inducible	  factor-­‐1	  
HLA	   	   human	  leukocyte	  antigen	  
HMBG1	   	   high-­‐mobility	  box	  group	  1	  
ICAM-­‐1	   	   intracellular	  adhesion	  molecule-­‐1	  
IFN-­‐g	   	   interferon	  gamma	  
IL	   	   interleukin	  
IP-­‐10	   	   IFN-­‐g-­‐inducible	  protein	  10	  
IRI	   	   ischemia-­‐reperfusion	  injury	  
i.v.	   	   intravenously	  
KLF-­‐2	   	   Krüppel-­‐like	  factor-­‐2	  
LFA1	   	   leukocyte	  function	  antigen	  1	  
MHC	   	   major	  histocompatibility	  complex	  
NF-­‐AT	   	   nuclear	  factor	  of	  activated	  T	  cells	  
NF-­‐κB	   	   nucleic	  factor	  kappa	  B	  
PAMP	   	   pathogen-­‐associated	  molecular	  pattern	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PBS	   	   phosphate-­‐buffered	  saline	  
PC	   	   pericyte	  
PMNC	   	   polymorphonuclear	  cell	  
Rbc	   	   red	  blood	  cell	  
RhoA	   	   Ras	  homolog	  gene	  family	  member	  A	  
ROR	   	   retinoic	  acid	  receptor-­‐related	  orphan	  receptor	  
ROS	   	   reactive	  oxygen	  species	  
RT-­‐PCR	   	   reverse-­‐transcription	  polymerase	  chain	  reaction	  
s.c.	   	   subcutaneously	  
SLO	   	   secondary	  lymphoid	  organ	  
SMA	   	   smooth	  muscle	  actin	  
SMC	   	   smooth	  muscle	  cell	  
STAT	   	   signal	  transducer	  and	  activator	  of	  transcription	  
TGF	   	   transforming	  growth	  factor	  
Th	   	   T	  helper	  cell	  
TLR	   	   Toll-­‐like	  receptor	  
TNFa	   	   tumor	  necrosis	  factor	  alpha	  
TnT	   	   troponin	  T	  
TOR	   	   target	  of	  rapamycin	  
Treg	   	   regulatory	  T	  cell	  
VCAM-­‐1	   	   vascular	  endothelial	  growth	  factor-­‐1	  
VE-­‐cadherin	   	   vascular	  endothelial	  cadherin	  
WF	   	   Wistar	  Furth	  rat	  
	  




Heart	  transplant	  is	  disconnected	  from	  the	  circulation	  and	  preserved	  
in	   hypothermia	   before	   transplantation.	   Paradoxically,	  
revascularization	   of	   the	   heart	   transplant	   results	   in	   ischemia-­‐
reperfusion	   injury	   described	   as	   myocardial	   injury,	   microvascular	  
dysfunction,	  and	  innate	  and	  adaptive	  immune	  activation.	  The	  innate	  
response	   consists	   mainly	   of	   neutrophils	   and	   macrophages	   and	  
innate	   lymphoid	   cells	   and	  may	   lead	   to	   sustained	  adaptive	   immune	  
response	   leading	   to	   chronic	   rejection	   and	   late	   graft	   failure.	   The	  
heart	   is	   especially	   susceptible	   for	   lack	   of	   oxygen;	   therefore,	   the	  
ischemic	  time	  in	  clinical	  practice	  is	  critical.	  Prolonged	  ischemic	  time	  
–	   due	   to	   long	   distance	   between	   hospitals	   or	   technically	   difficult	  
operation	   –	   is	   an	   independent	   risk	   factor	   for	   primary	   graft	  
dysfunction	  and	  chronic	  rejection.	  
	  
Angiopoietin-­‐1	   and	   -­‐2	   (Ang1	   and	   2)	   are	   vascular	   growth	   factors	  
binding	   to	   Tie2	   receptor	   with	   indispensible	   role	   in	   embryonic	  
vascular	   development,	   but	   also	   in	   endothelial	   maintenance	   in	  
mature	   vasculature.	   Vascular	   supporting	   cells	   constantly	   secrete	  
Ang1,	   which	   maintains	   the	   endothelium	   in	   quiescent	   state.	   In	  
contrast,	  Ang2	  is	  produced	  and	  released	  from	  the	  endothelial	  cells	  in	  
response	   to	   stress	   stimuli,	   such	   as	   hypoxia	   and	   inflammation,	  
destabilizing	   and	   activating	   the	   endothelium	   in	   order	   to	   ease	  
inflammatory	  cell	  accumulation	  and	  transmigration.	  	  
	  
 13 
This	  study	  utilized	  experimental	  animal	  model	  to	  describe	  the	  effect	  
of	   cardiac	   allograft	   ischemia-­‐reperfusion	   injury	   on	   innate	   immune	  
activation	   and	   adaptive	   immune	   responses,	   such	   as	   the	  
development	   of	   acute	   and	   chronic	   rejection.	   This	   study	   further	  
investigated	   the	   effects	   of	   either	   activating	   or	   inhibiting	   the	  
angiopoietin/Tie2-­‐signaling	   pathway	   in	   this	   disease	   process.	   The	  
results	   show	   that	   prolonged	   hypothermic	   preservation	   enhanced	  
ischemia-­‐reperfusion	   injury-­‐related	   innate	   immune	   activation	   and	  
adaptive	   immune	   and	   worsened	   the	   prognosis	   of	   the	   cardiac	  
allografts.	   Analysis	   of	   samples	   from	   clinical	   heart	   transplant	  
recipients	   revealed	   increase	   in	  peripheral	  blood	  Ang2	   levels	  during	  
the	  first	  day	  after	  the	  operation.	  Similar	  findings	  were	  evident	  in	  the	  
recipients	  of	  rat	  cardiac	  allografts.	  
	  
Ang1	  was	  proven	  protective	  when	  injected	  into	  allograft	  coronaries	  
prior	  to	  the	  preservation:	  the	  treatment	  stabilized	  the	  endothelium,	  
reduced	   myocardial	   injury	   and	   inflammation,	   and	   hindered	   the	  
development	   of	   chronic	   rejection.	   Donor	   heart	   treatment	   with	  
Ang2-­‐blocking	   antibody	   had	   similar	   effects	   on	   endothelium,	   but	  
further	   inhibited	   the	   activation	   of	   endothelial	   cells,	   acute	   and	  
chronic	   rejection.	   Furthermore,	   recipient	   treatment	   with	   multiple	  
doses	   of	   the	   anti-­‐Ang2	   antibody	   immediately	   after	   transplantation	  
significantly	   prolonged	   allograft	   survival	   and	   had	   superior	   effect	  
when	  compared	  to	  heart	  donor	  treatment.	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Primary	   and	   late	   graft	   dysfunction,	   either	   due	   to	   ischemia-­‐
reperfusion	   injury,	  or	  acute	  and	  chronic	  rejection,	   limit	  the	  survival	  
of	   patients	   with	   solid	   organ	   transplant.	   According	   to	   this	   study,	  
targeting	   Ang/Tie2-­‐signaling	   prevents	   early	   allograft	   endothelial	  
activation	  and	  inflammatory	  cell	  accumulation.	  Of	  studied	  treatment	  
protocols,	   early	   systemic	   recipient	   treatment	   with	   anti-­‐Ang2	  
antibody	   had	   the	   most	   robust	   effect	   in	   preventing	   allograft	  
dysfunction.	  Ang2-­‐targeted	  antibody	   treatment	  would	  have	   clinical	  
implications	   in	   induction	   therapy	   of	   transplant	   patients,	   as	   the	  
dosage	  of	  other	  immunosuppressive	  drugs	  may	  be	  lowered	  and	  the	  
adverse	  side	  effects	  of	  these	  drugs	  avoided.	  These	  results	  encourage	  
further	   studies	   to	   determine	   the	   clinical	   significance	   of	   Ang/Tie2-­‐
pathway	  modification.	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INTRODUCTION	  
Cardiovascular	   diseases	   are	   the	   leading	   cause	  of	   death	   in	  Western	  
countries.	   After	   advances	   in	   surgical	   techniques	   and	   the	  
introduction	   of	   immunosuppressive	   medication,	   cardiac	  
transplantation	  has	  become	  plausible	  treatment	  for	  many	  end-­‐stage	  
heart	  diseases.	   The	   shortage	  of	  organ	  donors	   limits	   the	  availability	  
of	  heart	  transplants	  and	  presents	  challenges	  to	  donor	  management.	  	  
Acute	  rejection,	  primary	  graft	  dysfunction,	  infections,	  malignancies,	  
and	   chronic	   allograft	   dysfunction	   limit	   the	   survival	   of	   cardiac	  
transplant	   patients.	   Of	   these,	   acute	   rejection	   and	   infections	   are	  
effectively	   managed	   with	   adjustments	   in	   immunosuppressive	  
medication	   and	   antibiotics;	   however,	   the	   side	   effects	   of	  
immunosuppressive	  drugs	  and	  the	  development	  of	  chronic	  rejection	  
continue	  to	  puzzle	  the	  clinicians	  and	  scientists.	  	  
Angiopoietins	  are	  vascular	  growth	  factors	  with	   indispensible	  role	   in	  
embryonic	   vascular	   development,	   but	   also	   in	   the	   stabilization	   of	  
mature	  vasculature.	  The	  angiopoietin	  signaling	  has	  been	  suggested	  a	  
potential	   immunomodulatory	   pathway	   in	   regulating	   microvascular	  
dysfunction	  and	  inflammation	  after	  cardiac	  transplantation.	  
The	  purpose	  of	   this	   study	  was	   to	   characterize,	   in	   experimental	   rat	  
cardiac	   transplantation	   model,	   the	   effects	   of	   ischemia-­‐reperfusion	  
injury	  on	  transplant	   inflammation	  and	  to	  elaborate	  the	  therapeutic	  
potential	   of	   angiopoietin-­‐1	   supplementation	   and	   angiopoietin-­‐2	  
blocking	  in	  this	  setting.	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REVIEW	  OF	  THE	  LITERATURE	  
	  
1.	  Clinical	  heart	  transplantation	  
	  
1.1.	  Background	  
The	   first	   documentations	   of	   tissue	   replacement	   are	   based	   on	   the	  
work	   of	   Gasparo	   Tagliacozzi	   –	   an	   Italian	   surgeon	   performing	  
successful	   autologous	   skin	   transplantations	   in	   the	   16th	   century.	  He	  
also	   repeatedly	   failed	  with	   allogeneic	   transplantations,	   introducing	  
the	   idea	   of	   rejection	   in	   his	   publication	  De	   Curtorum	   Chirurgia	   per	  
Instionem	  in	  1596.	  Alexis	  Carrel	  and	  Charles	  Guthrie	  developed	  new	  
suturing	   techniques	   for	   transplanting	   arteries	   and	   veins,	  
subsequently	   enabling	   vascular	   anastomosis	   operations	   and	   solid	  
organ	  transplantation	  (Carrel	  and	  Guthrie	  1905).	  Joseph	  Murray	  and	  
J.	  Hartwell	  Harrison	  performed	  the	  first	  technically	  successful	  kidney	  
transplantation	  between	  identical	  twins	   in	  1954	  (Guild	  et	  al.	  1955),	  
raising	   further	   interest	   in	   clinical	   solid	   organ	   transplantation.	  
Eventually,	   the	   development	   of	   heart-­‐lung	   machine	   enabled	  
surgeons	  to	  perform	  open-­‐heart	  surgery,	  and	  Christiaan	  Barnard	  to	  
perform	   the	   first	   allogeneic	  heart	   transplantation	   in	  1967	   (Barnard	  
1967).	  The	  first	  patient	  died	  unfortunately	  due	  to	  pneumonia	  early	  
after	   the	   successful	   operation.	   Nevertheless,	   Barnard	   inspired	  
others	   to	   establish	   several	   heart	   transplantation	   programs.	   Acute	  
rejection	   resulting	   from	   tissue	   type	  mismatching	  was	   fatal	   to	  most	  
of	   the	   recipients,	   however,	   and	   the	   hype	   quickly	   subsided.	   The	  
introduction	   of	   immunomodulatory	   drugs	   –	   corticosteroids,	  
azathioprine,	  and	  most	  importantly	  cyclosporine	  in	  1976	  (Borel	  et	  al.	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1976)	   –	   enabled	   long-­‐time	   survival	   of	   recipient	   and	   finally	   made	  
solid	   organ	   transplantation	   a	   plausible	   treatment	   for	   many	   end-­‐
stage	  diseases.	  
	  
1.2.	  General	  histology	  of	  the	  heart	  
Histologically,	   the	   heart	   consists	   of	   myocardium,	   supporting	  
connective	  tissue,	  and	  vascular	  structures.	  Vascular	  structure	  can	  be	  
divided	   into	   large	   coronary	   arteries,	   veins,	   arterioles,	   venules,	  
capillaries,	  and	  lymphatic	  vessels.	  Lymphatic	  vessels	  are	  responsible	  
for	   trafficking	   inflammatory	   cells	   from	   the	   heart	   into	   secondary	  
lymphatic	   organs.	   The	   vasculature	   feeds	   the	   myocardium	   with	  
oxygen	  and	  nutrients,	  but	  also	  enables	  circulating	  inflammatory	  cells	  
to	   enter	   the	   tissue.	   Mesenchyme	   derived	   pericytes	   (PC),	   smooth	  
muscle	  cells	  (SMC),	  fibroblasts,	  and	  extra-­‐cellular	  matrix	  (ECM)	  form	  
the	   connective	   tissue	   surrounding	   and	   supporting	   the	   vascular	  
structures	   and	   the	   myocardium.	   The	   myocardium	   is	   formed	   by	  
delicately	   organized	   and	   interconnected	   cardiomyocytes	   that	   are	  
responsible	  for	  the	  contractile	  function	  of	  the	  myocardium.	  
	  
Endothelial	   cells	   (EC)	   line	   the	   inner	   lumen	   of	   the	   blood	   vessels,	  
cardiac	  chambers,	  and	  the	  lymphatics	  forming	  a	  barrier	  between	  the	  
circulation	  and	  the	  tissues.	  EC	  play	   important	  role	   in	   inflammation,	  
as	  inflammatory	  cells	  must	  pass	  through	  the	  endothelium	  in	  order	  to	  
reach	   target	   tissue.	   As	   a	   response	   to	   inflammation,	   EC	   express	  
adhesion	   molecules	   on	   their	   luminal	   surface.	   These	   adhesion	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molecules	   enable	   circulating	   leukocytes	   to	   attach	   to	   vascular	  wall,	  
slow	  down,	  and	  eventually	  transmigrate	  through	  the	  endothelium.	  
	  
All	   cells	   express	   self-­‐antigens	   on	   their	   cell	   surface	   with	   major	  
histocompatibility	   complex	   (MHC)	   class	   I	   receptors.	   Antigen-­‐
presenting	  cells	  (APC;	  macrophages	  and	  dendritic	  cells)	  also	  express	  
MHC	  class	  II	  receptors	  and	  are	  able	  to	  present	  foreign	  peptides	  –	  i.e.	  
non-­‐self	   antigens	   –	   to	   T	   cells	   with	   these	   receptors.	   In	   MHC-­‐
mismatched	   organ	   transplantation,	   the	   donor	   tissue	   type	   differs	  
from	   the	   recipient	   tissue	   type	   –	   the	   transplant	   is	   therefore	  
allogeneic	  and	  called	  an	  allograft.	  
 
1.3.	  Indications,	  patient	  characteristics,	  and	  outcome	  
The	  International	  Society	  of	  Heart	  and	  Lung	  Transplantation	  (ISHLT)	  
Registry	   data	   show	   that	   between	   2006	   and	   2012,	   22	   318	   adult	  
transplantations	   have	   been	   performed	   around	   the	   world	   with	   the	  
most	  common	  indications	  being	  non-­‐ischemic	  cardiomyopathy	  (54%	  
of	  the	  patients)	  and	  coronary	  artery	  disease	  (37%).	  Other	  indications	  
were	   valvular	   (2.8%),	   congenital	   heart	   disease	   (2.9%),	   and	  
retransplantation	  (2.5%).	  Over	  35%	  of	  patients	  were	  bridged	  to	  the	  
transplantation	   with	   mechanical	   circulatory	   assist	   devices.	   The	  
median	  age	  of	  the	  heart	  transplant	  recipients	  was	  54	  years,	  and	  the	  
median	   age	   of	   the	   donors	   was	   35	   years.	   The	   cause	   of	   death	   for	  
organ	   donation	   was	   head	   trauma	   (46	   %),	   stroke	   (24%),	   or	   other	  
(30%)	  (Lund	  et	  al.	  2013).	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The	  survival	  of	  cardiac	  transplant	  recipients	  has	  changed	  little	  during	  
the	  last	  30	  years;	  the	  median	  survival	  of	  cardiac	  transplant	  recipients	  
is	   11	   years,	   however,	   patients	   surviving	   the	   first	   year	   after	   the	  
transplantation	   have	   median	   survival	   of	   14	   years	   (Stehlik	   et	   al.	  
2011).	   The	   latest	   data	   shows	   that	   1-­‐year	   survival	   of	   all	   cardiac	  
transplant	   patients	   is	   81%,	   and	   5-­‐year	   survival	   is	   69%.	   Figure	   1	  
demonstrates	   the	   median	   survival	   of	   transplant	   recipients	   on	  
different	   decades.	   The	   patient	   mortality	   is	   the	   highest	   during	   the	  
first	   year	   after	   the	   transplantation	   due	   to	   graft	   failure	   (36%	   of	  
deaths),	   non-­‐CMV	   infections	   (12%),	   acute	   rejection	   (4%),	   or	   other	  
reasons	   (46%).	   After	   the	   first	   year,	   graft	   failure,	   cardiac	   allograft	  
vasculopathy,	   and	   malignancies	   are	   the	   main	   survival-­‐limiting	  


















Figure	   1.	   The	   median	   survival	   of	   all	   cardiac	   transplant	   patients	  
operated	  between	  1982-­‐2011.	  Modified	  from	  Stehlik	  et	  al	  2013.	  
Average annual center heart transplant volume (all
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After	   the	   transplantation,	   the	   patients	   usually	   gain	   significant	  
improvement	  of	  life	  and	  can	  perform	  normally	  in	  daily	  activities.	  The	  
Registry	   data	   show,	   however,	   that	   only	   35%	   of	   the	   recipients	   are	  
employed	   1	   year	   after	   the	   transplantation,	   and	   46%	   at	   3	   years,	  
possibly	  due	  to	  regional	  employer-­‐related	  factors	  (Lund	  et	  al.	  2013).	  
	  
1.4.	  Risk	  factors	  
Immunologic	   and	   non-­‐immunologic	   factors	   pose	   risks	   to	   allograft	  
and	   patient	   survival.	   The	   donor-­‐derived	   non-­‐immunologic	   factors	  
are	   the	   cardiovascular	   status	   of	   the	   donor,	   the	   body-­‐mass	   index,	  
blood	   glucose	   levels	   and	   direct	   donor	   organ	   trauma.	   Immunologic	  
risk	   factors	   include	   donor	   brain	   death,	   tissue-­‐type	   mismatch	  
between	   the	   donor	   and	   the	   recipient,	   and	   recipient	   antibody	  
production.	   Donor	   brain	   death	   produces	   systemic	   cytokine	   storm	  
making	  the	  grafts	  even	  more	  susceptible	  to	  IRI	  and	  rejection	  (Takada	  
et	  al.	  1998;	  Wilhelm	  et	  al.	  2000).	  
	  
Due	   to	   the	   acute	   nature	   of	   cardiac	   diseases	   leading	   to	  
transplantation	   and	   shortage	   of	   organ	   donors,	   cardiac	  
transplantations	  are	  performed	  between	  donors	  and	  recipients	  with	  
mismatching	   tissue	   type,	   or	   major	   histocompatibility	   class	   (MHC;	  
human	  leukocyte	  antigen,	  HLA,	  in	  humans).	  Furthermore,	  due	  to	  the	  
shortage	  of	  organ	  donors,	  older	  and	  sicker	  patients	  are	  accepted	  as	  
donors.	  Episodes	  of	  acute	  rejection	  are	  common	  during	  the	  first	  year	  
after	  transplantation,	  as	  25%	  of	  patients	  are	  diagnosed	  with	  mild-­‐to-­‐
severe	   acute	   rejection.	   However,	   acute	   rejection	   is	   efficiently	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treated	   with	   immunosuppressive	   medication,	   as	   acute	   rejection	  
accounts	   only	   4%	   of	   deaths	   during	   the	   first	   year.	   The	   age	   of	   the	  
donor	  has	  linear	  correlation	  with	  the	  risk	  of	  mortality	  during	  the	  first	  
year	   after	   the	   transplantation.	   Similarly,	   prolonged	   allograft	  
ischemia	  –	  especially	  when	  exceeding	  200	  min	  –	   is	  associated	  with	  
increased	  early	  mortality	  risk.	  Other	  recipient-­‐derived	  risk	  factors	  for	  
early	  mortality	  are	   renal	  dysfunction,	  and	   the	  need	   for	  mechanical	  
circulatory	  support	  before	  transplantation.	  In	  addition	  to	  the	  1-­‐year	  
risk	   factors,	   risk	   factors	   for	  mortality	   during	   the	   first	   5	   years	   after	  
transplantation	   include	   episodes	   of	   acute	   rejection,	   the	   need	   for	  
dialysis	  or	  treated	  infection	  during	  hospitalization,	  and	  the	  absence	  
of	   certain	   immunosuppressive	   drugs	   1	   year	   after	   the	  
transplantation.	  Interestingly,	  donor	  age	  and	  ischemic	  time	  continue	  
to	  affect	  the	  survival	  of	  the	  recipients	  15	  years	  after	  transplantation	  
(Stehlik	  et	  al.	  2012).	  
	  
Immunosuppression	  fails,	  however,	  to	  protect	  the	  allograft	  and	  the	  
recipient	   from	   several	   important	   risk	   factors:	   ischemia-­‐reperfusion	  
injury,	  chronic	  rejection,	  the	  toxicity	  of	  immunosuppressive	  therapy,	  
and	   the	   exposure	   to	   infections.	   Episodes	   of	   acute	   rejection	   are	  
linked	   to	   chronic	   rejection	   development,	   and	   depending	   on	   the	  
severity	  of	   rejection,	   even	  one	  acute	   rejection	   requiring	   treatment	  
decreases	  the	  overall	  survival	  of	  the	  patients.	  	  
	  
The	  use	  of	   immunosuppressive	  medication	   is	  necessary	   to	  prevent	  
allograft	   rejection,	   but	   inhibition	   of	   the	   normal	   function	   of	   T	   cells	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increases	   the	   risk	   of	   infections.	   Viral	   infections	   pose	   the	   greatest	  
risks	   to	   solid	   organ	   transplant	   recipients,	   but	   also	   to	   the	   allograft	  
itself.	  Cytomegalovirus	  (CMV)	  infection	  increases	  the	  risk	  of	  allograft	  
rejection	   and	   cardiac	   allograft	   vasculopathy.	   Immunosuppression	  
also	   increases	   the	   risk	   of	   malignancies.	   The	   incidence	   of	   non-­‐skin	  
malignancies	  increases	  progressively	  and	  accounts	  for	  20%	  beyond	  5	  
years	  after	  transplantation	  (Stehlik	  et	  al.	  2012).	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2.	  Ischemia-­‐reperfusion	  injury	  
	  
2.1.	  Ischemia	  and	  hypothermia	  
The	  procurement	  of	  heart	   transplants	   requires	   that	   the	  blood	   flow	  
to	   the	   organ	   be	   stopped	   for	   the	   transportation	   and	   during	   the	  
surgery.	   Lack	  of	   circulation	   renders	   the	   transplant	   into	  oxygen	  and	  
nutrient	   deprived	   ischemic	   state.	   Current	   organ	   preservation	  
techniques	   rely	   on	   cooling	   of	   the	   allograft	   (Jacobs	   et	   al.	   2010).	  
Ischemia	  results	  in	  accumulation	  of	  anaerobic	  metabolites,	  changes	  
in	   electrolyte	   balance,	   and	   hypoxic	   tissue	   injury	   (McCord	   1985).	  
Ischemic	  time	  depends	  on	  the	  distance	  between	  the	  donor	  hospital	  
and	   the	   transplantation	   center,	   and	   with	   heart	   transplantation,	   is	  
approximately	   3	   hours	   (Stehlik	   et	   al.	   2012).	   The	   kidney,	   however,	  
endures	   ischemia	   better,	   and	   can	   be	   transplanted	   even	   after	   16	  
hours	   of	   ischemia	   (Southard	   and	   Belzer	   1995).	   Transplantation-­‐
related	   ischemia	   is	   divided	   into	   cold	   and	  warm	   ischemia,	   of	  which	  
cold	   ischemia	   is	   regarded	   as	   organ	   protective	   and	   warm	   ischemia	  
organ	  damaging	  phase.	  Physiologically,	  during	  hypothermia,	  the	  cell	  
metabolism	  and	  oxygen	  consumption	  are	   reduced,	  whereas	  during	  
warm	   ischemia,	   the	   tissue	   remains	   metabolically	   active	   but	   lacks	  
oxygen	   and	   nutrients	   driving	   itself	   into	   anaerobic	   state.	  
Furthermore,	  hypothermia	  protects	  endothelial	  cells	  from	  apoptosis	  
(Yang	   et	   al.	   2009).	   Ischemia,	   on	   the	   other	   hand,	   results	   in	  
mitochondrial	   damage	   and	   release	   of	   reactive	   oxygen	   species,	  
accumulation	  of	  lactate,	  and	  downregulation	  of	  Krüppel-­‐like	  factor	  2	  
(KLF2)	  expression,	  as	  endothelial	  shear	  stress	   is	  diminished	  (Dekker	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et	  al.	  2002).	  KLF2	  is	  essentially	  involved	  in	  vascular	  development	  and	  
sustaining	  physiological	  quiescence	  by	  negatively	  regulating	  vascular	  
inflammation,	   permeability	   and	   angiogenesis	   (SenBanerjee	   et	   al.	  
2004;	  Bhattacharya	  et	  al.	  2005;	  Dekker	  et	  al.	  2006;	  Lin	  et	  al.	  2006).	  	  
	  
Hypoxia-­‐inducible	  factor-­‐1	  (HIF1)	  is	  a	  transcription	  factor	  constantly	  
produced	  in	  various	  cell	  types	  in	  response	  to	  tissue	  hypoxia	  and	  it	  is	  
rapidly	   degraded	   in	   normoxia	   by	   von	  Hippel-­‐Lindau	   protein	   (Wang	  
and	  Semenza	  1993;	  Maxwell	  et	  al.	  1999).	  HIF1	  affects	  wide	  range	  of	  
downstream	   proteins,	   most	   relevant	   to	   microvascular	   dysfunction	  
being	  vascular	  endothelial	  growth	  factor	  (VEGF),	  angiopoietin-­‐1,	  and	  
angiopoietin-­‐2	   (Semenza	   2014).	   VEGF	   is	   pro-­‐angiogenic	   and	   pro-­‐
inflammatory	  growth	   factor,	  partly	   inducing	   its	   effects	   via	   increase	  
in	  endothelial	  permeability	  and	   recruiting	   smooth	  muscle	   cells	  and	  
endothelial	   cells	   to	   form	   new	   vessels	   (Yancopoulos	   et	   al.	   2000).	  
VEGF	   also	   induces	   adhesion	   molecule	   expression	   on	   the	   luminal	  
surfaces	   of	   the	   EC,	   luring	   inflammatory	   cells	   to	   the	   site	   of	   it’s	  
secretion	   (Kim	  et	  al.	  2001a).	   Interestingly,	  KLF2	  plays	  major	   role	   in	  
ischemic	  allograft	  as	  it	  also	  regulates	  HIF1	  expression	  (Kawanami	  et	  
al.	  2009).	  Figure	  2	  describes	  the	  factors	  involved	  and	  their	  interplay.	  
 
2.2.	  Reperfusion	  and	  re-­‐oxygenation	  
Revascularization	   of	   the	   transplant	   is	   vital	   for	   the	   organ	   but,	  
paradoxically,	   results	   in	   ischemia-­‐reperfusion	   injury	   (IRI).	  
Reperfusion	   of	   ischemic	   tissue	   with	   oxygenated	   blood	   results	   in	  
release	  of	  lactate,	  reactive	  oxygen	  species	  (ROS),	  capillary	  perfusion	  
and	  permeability	  disorder,	  endothelial	  activation,	  and	  inflammatory	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cell	  influx	  (Eltzschig	  and	  Carmeliet	  2011;	  Lampe	  and	  Becker	  2011).	  In	  
allogeneic	  environment,	   initial	  macrophage	  and	  neutrophil	   influx	   is	  
followed	  immediately	  by	  sustained	  NK	  and	  T	  cell	  infiltration	  (El-­‐Sawy	  
et	  al.	  2004).	  Therefore,	  IRI	  of	  allogeneic	  solid	  organ	  transplant	  differs	  
from	  IRI	  of	  other	  origin,	  such	  as	  revascularization	  in	  acute	  coronary	  
syndrome	  and	   in	  stroke.	   IRI	  of	   transplant	   is	   referred	  as	  Tx-­‐IRI	   from	  
now	  on	  to	  emphasize	  the	  importance	  of	  the	  difference.	  
	  
The	   IRI	   induces	   the	   release	   of	   endogenous	   molecules	   called	  
danger/damage-­‐associated	   molecular	   patterns	   (DAMP),	   which	   are	  
structural	   proteins	   normally	   bound	   to,	   or	   part	   of	   the	   extracellular	  
matrix.	  These	  molecules	  are	  recognized	  by	  the	  TLR-­‐receptors	  of	  the	  
innate	   immune	   system	   cells,	  which	   in	   allogeneic	   environment	  may	  

















Figure	  2.	  The	  effects	  of	  hypoxia	  and	  ischemia	  on	  microvascular	  wall	  
in	   the	   heart.	   Ang,	   angiopoietin;	   COX,	   cyclooxygenase;	   ET-­‐1,	  
endothelin-­‐1;	  EC,	  endothelial	  cell;	  PC,	  pericyte;	  CMC,	  cardiomyocyte;	  
ICAM-­‐1,	   intracellular	   adhesion	   molecule-­‐1;	   IL,	   interleukin;	   HIF-­‐1,	  
hypoxia-­‐inducible	   factor-­‐1;	   Rbc,	   red	   blood	   cell;	   RhoA,	   Ras	   homolog	  
gene	   family	   member	   A;	   SMA,	   smooth	   muscle	   actin;	   TLR,	   Toll-­‐like	  
receptor;	  TNF-­‐a,	  tumor	  necrosis	  factor	  alpha;	  TnT,	  troponin	  T,	  VCAM-­‐
1,	   vascular	   endothelial	   growth	   factor-­‐1;	   VE-­‐cadherin,	   vascular	  
endothelial	  cadherin;	  VEGF,	  vascular	  endothelial	  growth	  factor.	  
	  
	  
2.3.	  Microvascular	  dysfunction	  
Hypoxia	   induces	   EC	   instability	   by	   formation	   of	   cell	   membrane	  
protrusion	   and	   disintegration	   (Aono	   et	   al.	   2000).	   Ischemia	   and	  








































but	   more	   importantly	   results	   in	   PC	   constriction	   reducing	  
microvascular	  blood	  flow	  and	  tissue	  perfusion	  (Yemisci	  et	  al.	  2009).	  
Rho	  GTPases	  Rac1,	  and	  RhoA	  regulate	  these	  membrane	  morphology	  
changes,	   and	   PC	   and	   SMC	   constriction.	   In	   detail,	   RhoA	   and	   Rac1	  
have	  opposite	  function	  in	  hypoxia/reoxygenation,	  as	  RhoA	  regulates	  
endothelial	   barrier	   function	   and	   stress-­‐fiber	   formation,	   whereas	  
Rac1	   is	   required	   for	   endothelial	   recovery.	   (Wang	   et	   al.	   2001)	   Rho-­‐
kinase	   phosphorylates	   adducin	   and	   therefore,	   phosphorylated	  
adducin	  may	  be	  regarded	  as	  a	  parameter	  for	  Rho	  activity	  (Fukata	  et	  
al.	  1999).	  
	  
The	   perfusion	   defect	   worsens	   allograft	   function	   and	   may	   inflict	  
fibrosis	   development.	   Tx-­‐IRI	   also	   induces	   EC-­‐EC	   junction	  disruption	  
and	   microvascular	   leakage.	   Leaky	   vessels	   are	   more	   susceptible	   to	  
tissue	  edema	  and	  inflammatory	  cell	   influx.	  IRI	  affects	  microvascular	  
endothelium,	   PC	   and	   underlying	   tissue	   resulting	   in	   microvascular	  
dysfunction,	   endothelial	   barrier	   function	   disruption	   and	  
cardiomyocyte	  damage	  in	  cardiac	  allografts	  (Tuuminen	  et	  al.	  2011).	  
The	  activation	  of	  EC	  during	   ischemia	  and	  Tx-­‐IRI	   induces	  expression	  
of	   endothelial	   cell	   adhesion	   molecules	   attracting	   circulating	  
macrophages,	   neutrophils,	   NK	   cells,	   and	   T	   cells.	   Therefore,	  
microvascular	   dysfunction	   results	   in	   local	   inflammation,	  
accumulation	   of	   inflammatory	   cells	   and	   innate	   and	   adaptive	  
immune	  activation	   in	   cardiac	  allografts	   (Carden	  and	  Granger	  2000;	  
Boros	  and	  Bromberg	  2006;	  Dumitrescu	  et	  al.	  2007).	  




3.1.	  Innate	  immune	  system	  
The	  innate	  immune	  system	  consists	  of	  plasma	  complement	  system,	  
circulating	   inflammatory	   cells,	   such	   as	   neutrophil	   granulocytes,	  
monocytes,	  and	  natural	  killer	  (NK)	  cells,	  and	  of	  circulating	  and	  tissue	  
residing	  macrophages,	   and	  dendritic	   cells	   (Janeway	  and	  Medzhitov	  
2002).	   It	   is	   congenital	   first-­‐line	  defense	  against	   invading	  pathogens	  
but	   is	   also	   responsible	   for	   the	   cleaning	   and	  degradation	  of	   injured	  
tissue	  (Xu	  et	  al.	  2006).	  The	  complement	  system	  may	  directly	  destroy	  
pathogens	   or	   help	   the	   other	   inflammatory	   cells	   to	   do	   so	   (Müller-­‐
Eberhard	  1986).	  
	  
Neutrophils	  and	  monocytes/macrophages	  are	  phagocytes	  capable	  of	  
internalizing	   and	   ingesting	   pathogens	   and	   particles.	   They	   originate	  
from	  same	  common	  myeloid	  progenitor	  cells	  and	  subsequently	  from	  
myeloblasts.	   Neutrophils	   are	   the	   first-­‐responders	   to	   inflammation,	  
and	  migrate	  to	  the	  site	  of	  inflammation	  within	  minutes	  with	  the	  help	  
of	  IL-­‐8-­‐	  and	  C5d-­‐mediated	  chemotaxis.	  They	  also	  need	  to	  adhere	  to	  
the	   vascular	   wall	   and	   transmigrate	   through	   the	   endothelium	   by	  
interacting	  with	  selectins,	  integrins,	  and	  adhesion	  molecules	  –	  most	  
predominantly	  P-­‐selectin,	   LFA-­‐1,	   ICAM-­‐1,	  and	  VCAM-­‐1.	  Neutrophils	  
have	  characteristic	  cytoplasmic	  granules	  containing	  substances,	  such	  
as	  myeloperoxidase	   (MPO),	   lysozyme,	   and	   collagenase	   that	   enable	  
them	   to	   degrade	   phagocytized	   bacteria	   and	   obliterate	   internalized	  
particles	  (Kolaczkowska	  and	  Kubes	  2013).	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Macrophages	  participate	  in	  host’s	  first-­‐line	  defense	  against	  invading	  
pathogens,	   but	   also	   take	  part	   in	   scavenging	   aging	   cells	   and	  debris.	  
Furthermore,	   macrophages	   are	   able	   to	   boost	   adaptive	   immune	  
response	  in	  transplantation	  by	  presenting	  internalized	  antigens	  to	  T	  
cells,	  but	  also	  directly	  attacking	  allogeneic	  T	  cells	  (Xu	  et	  al.	  2006;	  Liu	  
et	  al.	  2012;	  Canton	  et	  al.	  2013).	  	  
	  
Toll-­‐like	  receptors	  (TLR)	  of	  innate	  immune	  cells	  recognize	  pathogen-­‐
associated	   molecular	   patterns	   (PAMP),	   such	   as	   bacterial	  
lipopolysaccharide,	   lipoproteins,	   peptidoglycan,	   and	   flagellin,	   viral	  
DNA	  and	  RNA	  (Aderem	  and	  Ulevitch	  2000).	  When	  encountered	  with	  
appropriate	   ligand,	   TLR	   activates	   innate	   immune	   cells	   to	   induce	  
adaptive	  immune	  responses.	  Of	  10	  identified	  functional	  human	  TLR	  
(13	   in	   mouse	   and	   rat),	   TLR2	   and	   4	   also	   recognize	   endogenous	  
structural	  molecules	  exposed	  during	  tissue	  injury	  (Roach	  et	  al.	  2005;	  
Land	   2011).	   These	   danger/damage-­‐associated	   molecular	   patterns	  
(DAMP)	   include	   biglycan,	   fibrinogen,	   fibronectin,	   hyaluronic	   acid	  
(HA),	   heat-­‐shock	   proteins	   and	   high-­‐mobility	   group	   box	   1	   (HMGB1)	  
(Smiley	  et	  al.	  2001;	  Tsan	  and	  Gao	  2004;	  Schaefer	  et	  al.	  2005;	  Yu	  et	  
al.	   2006).	   TLR2	   or	   4	   activation	   on	   APC	   surface	   results	   in	   MyD88-­‐
dependent	   NF-­‐kB	   and	   mitogen-­‐activated	   protein	   kinase	   signaling,	  
and	  innate	  immune	  activation	  (Barton	  and	  Medzhitov	  2003).	  Innate	  
immune	   activation	   includes	   DC	   maturation	   seen	   as	   increased	  
superficial	   co-­‐stimulatory	  molecule	   expression,	   and	   release	   of	   pro-­‐
inflammatory	   chemokines	   and	   cytokines	   (Figure	   3)	   (Janeway	   and	  














Figure	  3.	  The	  activation	  and	  maturation	  of	   immature	  dendritic	  cells	  
upon	   encountering	   of	   danger/damage-­‐associated	   molecular	  
patterns,	  and	  allogeneic,	  foreign	  peptides.	  The	  DC	  recognize	  DAMPs	  
with	  TLR-­‐receptors	  and	  begin	  expressing	  proinflammatory	  cytokines	  
through	  NF-­‐kB	  transcription	   factor	  activation.	  CCR7,	  C-­‐C	  chemokine	  
receptor	   type	   7;	   CD,	   cluster	   of	   differentiation;	   DC,	   dendritic	   cell;	  
DAMP,	  danger/damage-­‐associated	  molecular	  patterns;	  MHC,	  major	  
histocompatibility	  complex;	  NF-­‐kB,	  nucleic	  factor	  kappa	  B;	  TLR,	  Toll-­‐
like	  receptor.	  	  
	  
	  
Maturation	   increases	   the	   superficial	   expression	   of	   costimulatory	  
molecules	   CD80,	   CD83,	   CD86,	   CD40.	   DC	   migration	   to	   secondary	  
lymphoid	  organs	  (SLO),	  such	  as	  lymph	  nodes	  and	  spleen	  is	  facilitated	  
by	  increased	  expression	  of	  CCR7	  –	  a	  receptor	  for	  constantly	  secreted	  
lymphatic	   chemokine	   CCL19	   and	   21	   (Banchereau	   and	   Steinman	  
1998;	   Förster	   et	   al.	   2008).	   Activation	   of	   DC	   is	   important	   step	   in	  
linking	  innate	  and	  alloimmune	  responses	  (Figure	  4).	  
































Figure	   4.	   Cross-­‐linkage	   of	   innate	   and	   adaptive	   immune	   responses	  
during	   ischemia-­‐reperfusion	   injury.	   CCL21,	   Chemokine	   (C-­‐C	   motif)	  
ligand	   21;	   CCR7,	   C-­‐C	   chemokine	   receptor	   type	   7;	   CD,	   cluster	   of	  
differentiation;	   CMC,	   cardiomyocyte;	   DAMP,	   danger/damage-­‐
associated	  molecular	  pattern;	  DC,	  dendritic	  cell;	  EC,	  endothelial	  cell;	  
IFN-­‐g,	   interferon	  gamma;	   IL,	   interleukin;	  PMNC,	  polymorphonuclear	  
cell;	   Th,	   T	   helper	   cell;	   TLR,	   Toll-­‐like	   receptor;	   VEGF,	   vascular	  




3.2.	  Alloimmune	  system	  
The	  alloimmune	  system	  consist	  of	  B	  and	  T	  cells,	  of	  which	  the	  latter	  
can	   be	   further	   divided	   into	   CD4+	   T	   helper	   cells	   (Th),	   and	   CD8+	  
cytotoxic	   lymphocytes	   (CTL).	  The	  CD4+	  T	  cells	  are	   further	  classified	  
into	   subtypes	  presented	   in	  Table	  1.	  CD4+CD25+FoxP3+	   subset	  of	  T	  














































tolerance.	   These	   cells	   are	  named	   regulatory	   T	   cells	   (Treg)	   for	   their	  
suppressive	  properties	  (Wood	  et	  al.	  2012;	  Lazarevic	  et	  al.	  2013).	  
	  
In	   direct	   allorecognition,	   the	   donor-­‐derived	   passenger	   DC	   and	  
macrophages	   of	   the	   allograft	   travel	   to	   SLO	   and	   present	   donor	  
peptides	   with	   MHC	   class	   I	   receptors	   directly	   to	   cytotoxic	   CD8+	   T	  
cells,	   or	   with	  MHC	   class	   II	   to	   naïve	   CD4+	   T-­‐cells.	   T	   cells	   may	   also	  
recognize	  foreign	  peptides	  directly	  on	  allograft	  endothelial	  cell	  MHC	  
class	  I	  receptors	  (Ali	  et	  al.	  2013).	  
	  
In	  indirect	  allorecognition,	  once	  the	  recipient	  APC	  encounter	  foreign	  
protein,	  they	  internalize	  it,	  activate	  and	  increase	  their	  expression	  of	  
CD80,	  CD83,	  CD86,	  and	  CCR7	  on	  their	  surfaces	  and	  migrate	  to	  SLO	  to	  
present	  the	  internalized	  foreign	  material	  to	  naïve	  CD4+	  T	  cells	  with	  
MHC	   class	   II	   receptors	   (Janeway	   and	   Medzhitov	   2002;	   Rossi	   and	  
Young	  2005;	  Kaczorowski	  et	  al.	  2007).	  The	  T	  cells	  recognize	  peptides	  
presented	  in	  MHC	  class	  II	  receptors	  with	  their	  T	  cell	  receptors	  (TCR),	  
and	   if	   accompanied	   with	   co-­‐stimulatory	   signal	   between	   CD28	   and	  
CD80/CD86,	   the	   transcription	   factor	   of	   activated	   T	   cells	   (NF-­‐AT)	   is	  
activated	   by	   calcineurin.	   This	   leads	   to	   interleukin-­‐2	   (IL-­‐2)	  
transcription	   and,	   by	   paracrine	   signaling	   through	   IL-­‐2R,	   to	   clonal	  
proliferation	  of	  alloreactive	  T	  cells	  (Figure	  5)	  (Lee	  et	  al.	  1994).	  
	  
In	   a	   relatively	   lately	   discovered	   phenomenon,	   semi-­‐direct	  
allorecognition,	  donor-­‐derived	  peptides	  are	  presented	  unprocessed	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to	   T	   cells	   by	   recipient	   APC.	   This	   constitutes	   a	   small	   minority	   of	  
allorecognition	  and	  probably	  has	  little	  clinical	  significance.	  
	  
	  
Table	   1.	   Different	   T	   helper	   cell	   subsets.	   IL,	   interleukin;	   IFN,	  
interferon;	   STAT,	   signal	   transducer	   and	   activator	   of	   transcription;	  
TGF,	  transforming	  growth	  factor;	  ROR,	  retinoic	  acid	  receptor-­‐related	  




Function	  normally	  /	  	  
In	  transplantation	  
Transcription	  factors	  
and	  hallmark	  cytokines	  	  
Th1	   Cellular	  immune	  defence;	  
boosts	  macrophage	  and	  
CD8+	  T	  cell	  killing	  ability	  /	  
Cell-­‐mediated	  rejection	  
	  
T-­‐bet;	  IL-­‐2,	  IL-­‐12,	  IFN-­‐γ,	  
STAT4	  
Th2	   Humoral	  immune	  defence;	  B	  
cell	  stimulation	  /	  Antibody-­‐
mediated	  rejection	  
	  
GATA3;	  IL-­‐4,	  IL-­‐10,	  
STAT6	  
Th3	   Mucosal	  immunity	  in	  the	  gut	  
/	  unknown	  
	  
IL-­‐4,	  IL-­‐10,	  TGF-­‐β	  
Th17	   Anti-­‐microbial	  immunity	  /	  
Cell-­‐mediated	  rejection	  
	  
RORγ, STAT3;	  IL-­‐6,	  IL-­‐17,	  
IL-­‐23	  	  
Treg	   Immune	  balance	  /	  
Tolerance?	  
	  

























Figure	  5.	  Antigen	  presentation	  and	  costimulation	  between	  dendritic	  
cell	   (DC)	   and	  naïve	   CD4+	   T	   cell.	   If	   accompanied	  with	   costimulatory	  
signal,	   antigen	   presentation	   results	   in	   clonal	   expansion	   of	  
alloreactive	   T	   cells.	   CD,	   cluster	   of	   differentiation;	  DC,	   dendritic	   cell;	  




Alloreactive	   cytotoxic	   CD8+	   T	   cells	   are	   the	   prime	   effector	   cells	  
responsible	  for	  allograft	   injury	  and	  may	   inflict	  graft	  rejection	   in	  the	  
absence	   of	   CD4+	   T	   cell	   help.	   Acute	   rejection	   is	   considered	   to	  
originate	  from	  direct	  allorecognition	  and	  from	  MHC	  class-­‐I	  signaling	  
between	  CD8+	  T	  cells	  and	  allogeneic	  cells,	  whereas	  chronic	  rejection	  
is	   indirect	   allorecognition-­‐mediated	   (Liu	   et	   al.	   1993;	   Rogers	   and	  
Lechler	  2001;	  Schmauss	  and	  Weis	  2008).	  
	  
Th17	  T	  cells	  produce	  mainly	  IL-­‐17A	  and	  participate	  normally	  in	  host	  
pathogen	   defense,	   but	   also	   in	   multiple	   autoimmune	   diseases	   and	  
chronic	   inflammation.	   IL-­‐17A	   has	   been	   linked	   to	   neutrophil	  














factor	  and	  CXC	  chemokines	  (Laan	  et	  al.	  1999;	  Ley	  et	  al.	  2006).	  IL-­‐23	  
signaling	  via	  IL-­‐23R	  is	  crucial	  for	  Th17	  T	  cells	  effector	  function	  and	  IL-­‐
17	   mediated	   inflammation	   (Korn	   et	   al.	   2009).	   The	   role	   of	   Th17	  
response	   in	   allograft	   rejection	   was	   demonstrated	   with	   T-­‐box21-­‐
deficient	  mice,	  which	  lack	  Th1	  alloimmune	  response.	  The	  findings	  of	  
Yuan	   et	   al.	   suggest	   that	   the	   absence	   of	   Th1-­‐transcription	   factor	   T-­‐
box21	   (murine	  analog	   for	  Tbet)	   results	   in	  clonal	  expansion	  of	   IL-­‐17	  
producing	   T	   cells	   and	   accelerated	   allograft	   rejection.	   (Yuan	   et	   al.	  
2008)	   Furthermore,	   in	  wild-­‐type	  mice,	   TLR-­‐signaling	   promotes	   IL-­‐6	  
and	   IL-­‐17-­‐dependent	   acute	   rejection	   bridging	   Th17	   response	   and	  
innate	  immune	  activation	  (Chen	  et	  al.	  2009).	  
	  
Tregs	  are	  a	  subset	  of	  T	  cells	  naturally	  originating	  from	  thymus	  with	  
important	   role	   in	   balancing	   immune	   system	   during	   everyday	   life,	  
especially	   during	  microbial	   infections	   and	   pregnancy.	   Disruption	   in	  
Treg	   population	   may	   result	   in	   unwanted	   conditions	   such	   as	  
autoimmune	  diseases,	  allergies,	  and	  tumor	  immunity.	  Furthermore,	  
generation	   of	   alloantigen-­‐specific	   Tregs	   may	   induce	   transplant	  
tolerance	   by	   inhibiting	   costimulatory	   signals	   of	   T	   cells	   and	   thus	  
preventing	   generation	   of	   alloreactive	   effector	   T	   cells.	   (Sakaguchi	  
2005;	  Ochando	  et	  al.	  2006)	  Recent	  findings	  suggest	  clinical	  potential	  
for	   adoptive	   transfer	   of	   ex	   vivo-­‐expanded	   antigen-­‐specific	   Tregs	  
generated	   from	   naïve	   T	   cells	   in	   prevention	   of	   allograft	   rejection	  
(Takasato	  et	  al.	  2014).	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3.5.	  Acute	  rejection	  
Fully	   allogeneic	   transplant	   is	   foreign	   tissue	   to	   the	   recipient	   and,	  
therefore,	   is	   considered	  a	   threat.	   PMC,	  macrophages,	   and	  NK	   cells	  
are	   the	   first	   allograft-­‐infiltrating	   inflammatory	   cells	   early	   after	   the	  
reperfusion.	   Leukocyte	   infiltration	   is	   physiological	   response	   to	   IRI	  
and	   occurs	   both	   in	   syn-­‐	   and	   allografts,	   and	  may	   inflict	   early	   graft	  
injury	  without	   antigen	  processing	  and	  allorecognition.	   In	   syngrafts,	  
this	  acute	   inflammation	  subsidizes	   in	  hours.	   In	  allografts,	  however,	  
the	  direct	  and	  indirect	  allorecognition	  produces	  alloreactive	  effector	  
T-­‐cells,	   which	   invade	   the	   allograft.	   The	   presence	   of	   CD8+	   T	   cells	  
boosts	   innate	   immune	   mediated	   inflammation	   and	   inflicts	  
prolonged	  neutrophil-­‐mediated	  response.	  The	  CD8+	  T-­‐cells	  are	  also	  
responsible	   for	   direct,	   MHC	   class-­‐I-­‐mediated	   destruction	   of	  
allogeneic	  tissue	  (El-­‐Sawy	  et	  al.	  2004).	  
	  
Hyperacute	   rejection	   of	   a	   solid	   organ	   transplant	   is	   a	   rare	  
phenomenon	   seen	   in	   sensitized	   recipients	   with	   donor-­‐specific	  
antibodies,	   resulting	   from	   pre-­‐existing	   antibodies	   against	  
incompatible	   ABO	   blood	   group	   or	   HLA-­‐antigens.	   The	   allograft	   is	  
destroyed	   within	   minutes	   by	   thrombosis	   and	   devascularization.	  
Hyperacute	  rejection	   is	   the	  main	   limitation	  for	  xenotransplantation	  
(Williams	  et	  al.	  1968;	  Mengel	  et	  al.	  2012).	  
	  
Acute	  cellular	   rejection	  results	   from	  alloreactive	  T	  cell	  proliferation	  
and	  infiltration	  after	  allorecognition.	  CD8+	  T	  cells	  and	  NK	  cells	  attack	  
foreign	  cells	  either	  through	  foreign	  peptide	  encountering	  with	  MHC	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class	   I	  receptor	  or	  via	  “non-­‐self”	  recognition.	  CD4+	  Th1-­‐type	  T	  cells	  
and	  macrophages	   are	   responsible	   for	   delayed	   hypersensitivity	   and	  
inflammation.	  CD4+	  Th2-­‐type	  T	  cells	  and	  B	  cells	  are	  responsible	  for	  
antibody-­‐mediated	   rejection.	   (Rogers	   and	   Lechler	   2001;	   Lakkis	   and	  
Lechler	  2013)	  Table	  2.	  describes	   the	  2004	   revised	  grading	  of	  acute	  
cellular	   and	   antibody-­‐mediated	   rejection	   in	   heart	   transplants	  
according	  to	  ISHLT	  consensus.	  	  
	  
Table	   2.	   International	   Society	   of	   Heart	   and	   Lung	   Transplantation	  
standardized	  grading	  of	  cardiac	  biopsy	  for	  acute	  cellular	  rejection	  (R)	  
and	   antibody-­‐mediated	   rejection	   (AMR).	  Modified	   from	   Stewart	   et	  
al.	  J	  Heart	  Lung	  Transplant,	  2005.	  
	  
Grade	  0	   No	  rejection	  
Grade	  1	  R,	  mild	   Interstitial	  and/or	  perivascular	  
infiltrate	  with	  up	  to	  1	  focus	  of	  
myocyte	  damage	  
Grade	  2	  R,	  moderate	   Two	  or	  more	  foci	  of	  infiltrate	  
with	  associated	  myocyte	  damage	  
Grade	  3,	  R	  severe	   Diffuse	  infiltrate	  with	  multifocal	  
myocyte	  damage	  ±	  edema,	  ±	  
hemorrhage	  ±	  vasculitis	  
	  
	  
AMR	  0	  	   Negative	  for	  acute	  antibody-­‐
mediated	  rejection	  
No	  histologic	  or	  immunopathologic	  




Positive	  for	  AMR	  
Histologic	  features	  of	  AMR	  
Positive	  immunofluorescence	  or	  
immunoperoxidase	  staining	  for	  





In	  order	  to	  prevent	  acute	  allograft	  rejection	  and	  to	  prolong	  allograft	  
survival,	   the	   alloimmune	   response	   is	   suppressed	   with	   various	  
immunosuppressive	   drugs	   (Table	   3).	   Usual	   clinical	   protocol	   with	  
triple-­‐drug	   maintenance	   therapy	   consists	   of	   steroids,	   calcineurin	  
inhibitor	   cyclosporine	   A	   or	   tacrolimus,	   and	   of	   antimetabolite	  
azathioprine	   or	   mycophenolate	   mofetil,	   or	   T	   cell	   proliferation	  
inhibitor	   sirolimus	   or	   everolimus.	   Induction	   therapy	   with	   anti-­‐
thymocyte	  globulin	  or	  with	  anti-­‐IL2R-­‐antibodies	  results	   in	  profound	  
perioperative	   immunosuppression.	   With	   immunosuppressive	  
medication,	   acute	   T-­‐cell-­‐mediated	   rejection	   is	   preventable.	   The	  
immunosuppressive	  drugs,	  however,	  have	  undesirable	   side	  effects,	  
and	  require	  constant	  monitoring.	  High	   level	  of	   immunosuppression	  
also	   increases	   the	   risk	  of	  opportunistic	   infections	   (Lindenfeld	  et	   al.	  
2004a;	  2004b;	  Baran	  2013).	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Table	  3.	  Immunosuppressive	  drugs,	  their	  mechanism	  of	  action,	  and	  
clinical	  use.	  AP-­‐1,	  activation	  protein-­‐1;	  IL,	  interleukin;	  NF-­‐kB,	  nucleic	  
factor	  kappa	  B;	  TOR,	  target	  of	  rapamycin.	  
	  
Drug	   Mechanism	   Use	  





Azathioprine	   Cell	  cycle	  inhibitor	  
of	  T	  (and	  B)	  cells	  
	  
Maintenance	  therapy	  (to	  
lesser	  extent)	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3.7.	  Chronic	  rejection	  	  
Chronic	   rejection	   in	   cardiac	   allografts	   is	   described	   histologically	   as	  
cardiac	   allograft	   vasculopathy	   (CAV)	   and	   clinically	   as	   allograft	  
dysfunction	   resulting	   probably	   from	   prolonged	   and	   sustained	  
chronic	  inflammation	  driven	  by	  ischemic	  injury	  and	  acute	  rejection,	  
and	   from	   subsequent	   vascular	   remodeling.	   The	   pathogenesis	   of	  
chronic	   rejection,	   however,	   is	   poorly	   understood	   but	   prognostic	  
factors	   include	  preoperative	  graft	   ischemia	   time,	  episodes	  of	  acute	  
rejection,	   donor	   age,	   and	   cytomegalovirus	   infection.	   In	   contrast	   to	  
common	   coronary	   artery	   disease,	   allograft	   vasculopathy	   is	  
histologically	   described	   as	   diffuse	   luminal	   occlusion	   of	   cardiac	  
arteries	  and	  fibrosis	  development.	  The	  incidence	  of	  cardiac	  allograft	  
dysfunction	  increases	  over	  time	  and	  limits	  the	  survival	  of	  transplant	  
patients.	  Current	  immunosuppressive	  treatment	  fails	  to	  prevent	  the	  
development	   of	   vasculopathy	   and	   cardiac	   fibrosis	   and	   subsequent	  
dysfunction,	  and	  the	  only	  effective	   treatment	   for	   the	  disease	   is	   re-­‐
transplantation	  (Tanaka	  et	  al.	  2005;	  Stehlik	  et	  al.	  2012).	  
	  
The	  scientific	  community	  generally	  considers	  indirect	  allorecognition	  
and	   sustained	   Th1-­‐	   and	   IFN-­‐g-­‐mediated	   alloimmune	   inflammation	  
the	  driving	   force	  behind	   the	  development	  of	   vasculopathy.	   Several	  
other	   factors,	   however,	   contribute	   to	   vascular	   inflammation	   and	  
microvascular	   dysfunction	   leading	   subsequently	   to	   graft	   failure	  
(Figure	   6).	   Therefore,	   a	   combination	   of	   chronic	   inflammation	   and	  
response-­‐to-­‐injury	  better	  describes	  the	  phenomenon.	  




























Figure	   6.	   The	   interactions	   between	   factors	   affecting	   the	  
pathogenesis	   of	   cardiac	   allograft	   dysfunction	   and	   vasculopathy	  
(modified	  from	  Schmauss	  and	  Weis,	  Circulation	  2008).	  
	  
Early	  innate	  immune	  response	  and	  following	  alloimmune	  activation	  
described	   above	   are	   the	   initiating	   events	   in	   pathological	   vascular	  
remodeling.	   Inflammatory	   cytokines	   IL-­‐1,	   IL-­‐6,	   and	   TNF-­‐α	   promote	  
vascular	   inflammation	   and	   SMC	   proliferation.	   Microvascular	  
dysfunction	   after	   cardiac	   transplantation	   results	   in	   disruption	   in	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no-­‐reflow	  phenomenon.	  No-­‐reflow	  occurs	  as	  a	  response	  to	  ischemic	  
insult	   when	   the	   small	   arterioles	   and	   capillaries	   remain	   contracted	  
and	  blood	  flow	  to	  the	  tissue	  is	  impaired,	  possibly	  due	  to	  contraction	  
of	   endothelial	   cells	   and	   pericytes.	   Due	   to	   loss	   of	   capillaries	   and	  
myocardial	  inflammation,	  the	  myocardium	  is	  gradually	  replaced	  with	  
fibrotic	   tissue,	   accompanied	   with	   impaired	   contractile	   function.	  
(Reffelmann	  et	  al.	  2003;	  Schmauss	  and	  Weis	  2008;	  Tuuminen	  et	  al.	  
2011)	   Chronic	   cardiac	   allograft	   dysfunction	  manifests	   histologically	  
as	   cardiac	   fibrosis	   and	   allograft	   vasculopathy,	   which	   in	   turn	   is	  
characterized	   clinically	   by	   diastolic	   dysfunction	   and	   heart	   failure	  
(Hollenberg	  et	  al.	  2001;	  Haddad	  et	  al.	  2012).	  	  
	  
Pollack	   et	   al.	   (2013)	   have	   recently	   reviewed	   extensively	   the	  
diagnostic	   methods	   of	   evaluating	   CAV.	   Diagnosis	   of	   CAV	   is	  
somewhat	   complicated,	   as	   the	   innervation	   of	   the	   heart	   is	  
interrupted	  after	  the	  transplantation	  and	  the	  recipients	  do	  not	  feel	  
any	  heart-­‐related	  chest	  pain.	  The	  progressive	  intimal	  stenosis	  results	  
ultimately	   in	   graft	   failure	   and,	   therefore,	   the	   clinical	   symptoms	  
implicating	   problems	   appear	   too	   late.	   Current	   clinical	   protocols	  
usually	  embrace	   routine	   transvenous	  biopsies	   taken	   regularly	   after	  
the	   transplantation.	   Angiography	   is	   the	   most	   usual	   method	   of	  
evaluating	   coronary	   arteries,	   however,	   the	   method	   is	   highly	  
susceptible	  for	  interpretation	  error,	  as	  the	  occluded	  arteries	  seem	  to	  
be	  in	  better	  shape	  than	  they	  actually	  are.	  Intravenous	  ultrasound	  is	  
the	   most	   reliable	   method	   of	   evaluating	   the	   degree	   of	   intimal	  
occlusion.	   Cardiac	   magnetic	   resonance	   is	   novel	   method	   of	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evaluating	   risk	   of	   CAV	   development	   and	   CAV-­‐associated	   changes,	  
but	  does	  not	  directly	  detect	  or	  determine	  severity	  of	  CAV	  (Hofmann	  
et	  al.	  2014;	  Braggion-­‐Santos	  et	  al	  2014).	  
	  
The	   incidence	   of	   CAV	   increases	   over	   time.	   According	   to	   the	   ISHLT	  
Registry	   data,	   approximately	   10%	   of	   patients	   are	   diagnosed	   with	  
CAV	  one	  year	  after	  the	  transplantation.	  At	  ten	  years,	  approximately	  
half	  of	  the	  patients	  have	  developed	  CAV-­‐associated	  changes.	  (Stehlik	  
et	   al.	   2012)	   Therapeutic	   options	   in	   the	   treatment	   of	   CAV	   remain	  
limited,	   as	   coronary	   dilatation	   with	   angioplasty	   or	   stenting,	   and	  
coronary	  by-­‐pass	  operations	  have	  resulted	  in	  high	  morbidity	  and	  are	  
nowadays	   considered	   as	   palliative	   procedures.	   (Halle	   et	   al.	   1995;	  
Bader	  et	  al.	  2006)	  Therefore,	  re-­‐transplantation	  remains	  as	  the	  only	  
definitive	   treatment	   for	   CAV,	   however,	   patients	   that	   have	  
undergone	   re-­‐transplantation	   have	   reduced	   survival	   after	   the	  
operation	  (Srivastava	  et	  al.	  2000;	  Johnson	  et	  al.	  2007).	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4.	  Angiopoietin	  pathway	  
	  
4.1.	  General	  
The	   angiopoietins	   are	   vascular	   growth	   factors	   consisting	   of	  
angiopoietin-­‐1,	  -­‐2,	  and	  -­‐4	  (Ang1,	  Ang2,	  Ang4),	  of	  which	  Ang1	  and	  -­‐2	  
act	   through	  their	   shared	  receptor	   tyrosine	  kinase	  Tie2	   (Jones	  et	  al.	  
2001).	  The	  physiological	  role	  of	  Ang4	  has	  not	  yet	  been	  defined.	  Tie1	  
and	   Tie2	   are	   endothelial	   cell	   membrane	   receptors	   with	   high	  
structural	  homology.	  Although	  discovered	  earlier	  than	  Tie2	  receptor,	  
little	   is	   known	   about	   the	   physiological	   role	   of	   Tie1	   receptor.	   Tie1	  
seems	   crucial	   for	   endothelial	   cell	   survival,	   but	   not	   vasculogenesis	  
(Partanen	  et	  al.	  1996).	  Tie1	  has	  been	  suggested	  to	  have	  blood	  flow-­‐
dependent	   impact	   on	   arteriosclerotic	   plaque	   formation,	   as	   Tie1	  
deletion	  reduces	  arteriosclerotic	  lesion	  formation	  (Woo	  et	  al.	  2011).	  
Tie1	   and	   Tie2	   both	   have	   cytoplasmic	   tyrosine	   kinase	   domains	   and	  
are	   composed	   of	   two	   extracellular	   IgG-­‐like	   domains,	   followed	   by	  
three	   EGF-­‐like	   domains,	   another	   Ig-­‐like	   domain,	   and	   three	  
fibronectin	  type	  III	  domains	  (Figure	  8).	  
	  
Angiopoietins	  regulate	  physiological	  microvascular	  integrity	  but	  also	  
pathophysiological	   dysfunction.	   Ang/Tie2-­‐signaling	   is	   essential	   for	  
embryonic	  development,	  as	  Tie2-­‐defiency	  results	  in	  early	  embryonic	  
lethality	  (Davis	  et	  al.	  1996).	  























Figure	  8.	   The	  angiopoietin/Tie2	   signaling	   system.	  Ang1	  and	  2	  both	  
ligate	   to	   the	   same	   Tie2	   receptor	   tyrosine	   kinase.	   Ang2	   acts	   as	   a	  
context-­‐dependent	   agonist	   or	   antagonist	   to	   the	   receptor.	   Tie2	  
phosphorylation	   results	   in	   activation	   of	   PI3K/Akt	   pathway	   and	  
downregulation	   of	   FOXO1	   transcription	   factor,	   which	   in	   turn	  
downregulates	  Ang2	  expression	   (modified	   from	  Augustin	   et	   al.	  Nat	  
Rev	  Mol	  Cell	  Biol	  2009).	  
	  
4.2.	  Angiopoietin-­‐1	  
Ang1	   has	   essential	   role	   in	   embryonic	   vascular	   development	   and	  
vessel	   maturation;	   Ang1-­‐deficient	   mice	   die	   early	   during	   the	  
embryogenesis	   (Hanahan	   1997).	   Ang1	   stabilizes	   the	   immature	   and	  
leaky	   vessels	   by	   promoting	   interactions	   between	   the	   ECs	   and	  
perivascular	  structures	   (Gamble	  et	  al.	  2000;	  Saharinen	  et	  al.	  2008),	  











2007).	   Ang1	   is	   constitutively	   secreted	   by	   endothelial	   supporting	  
cells,	  such	  as	  pericytes	  and	  SMC,	  but	  also	  by	  fibroblasts,	  and	  several	  
types	   of	   tumor	   cells	   (Davis	   et	   al.	   1996;	   Stratmann	   et	   al.	   1998;	  
Sugimachi	  et	  al.	  2003).	  
	  
Tie2	  phosphorylation	  by	  Ang1	   induces	   signaling	   cascade	   that	   leads	  
to	   recruitment	   of	   p85	   subunit	   of	   phophoinositide	   3-­‐kinase	   (PI3K),	  
and	  the	  activation	  of	  transcription	  factor	  Akt.	  Akt	  signaling	  promotes	  
survival-­‐associated	   pathways,	   and	   suppresses	   apoptotic	   pathways.	  
Interestingly,	   Akt	   also	   inactivates	   Ang2-­‐targeting	   forkhead	  
transcription	   factor	   FOXO1	   resulting	   in	   negative	   feedback	   loop	   on	  
Ang2	   production.	   On	   the	   other	   hand,	   inactivation	   of	   PI3K/Akt	  
signaling	   activates	   FOXO1	   and	   increases	   Ang2	   production	   and	   EC	  
destabilization	   (Papapetropoulos	   et	   al.	   2000;	   Kontos	   et	   al.	   2002;	  
Daly	  et	  al.	  2004;	  DeBusk	  et	  al.	  2004).	  	  
	  
Ang1/Tie2-­‐signaling	  regulates	  EC-­‐EC	  permeability	  by	  inhibiting	  VEGF-­‐
dependent	   adherens	   junction	   protein	   vascular	   endothelial	   (VE)-­‐
cadherin	   internalization	   from	   junctional	   complexes	   (Gavard	   et	   al.	  
2008).	  In	  addition,	  Ang1	  and	  Tie2	  form	  junctional	  complexes	  further	  
stabilizing	   endothelium,	   but	   also	   its	   binding	   to	   extracellular	  matrix	  
(Saharinen	  et	  al.	  2008).	  
	  
Ang1	   acts	   as	   an	   anti-­‐inflammatory	   cytokine	   as	   it	   inhibits	   leukocyte	  
recruitment	   by	   preventing	   VEGF-­‐induced	   endothelial	   adhesion	  
molecule	  expression	  and	  after	  LPS	  induced	  endotoxic	  shock	  (Kim	  et	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al.	  2001b;	  Witzenbichler	  et	  al.	  2005).	  In	  addition,	  Ang1	  induces	  KLF2	  
expression	   on	   endothelial	   cells	   counteracting	   VEGF-­‐mediated	  
VCAM-­‐1	   expression	   and	   inflammatory	   cell	   adhesion	   (Sako	   et	   al.	  
2009).	   Furthermore,	   Ang1/Tie2-­‐signaling	   inhibits	   NF-­‐kB-­‐mediated	  
inflammation	   via	   A20	   binding	   inhibitor	   of	   NF-­‐kB	   (ABIN)	   protecting	  
the	  endothelial	  cells	  from	  inflammation	  and	  apoptosis	  (Hughes	  et	  al.	  
2003;	  Tadros	  et	  al.	  2003).	  
	  
4.3.	  Angiopoietin-­‐2	  
Originally	  discovered	  1997	  as	  Ang1	  and	  Tie2	  receptor	  antagonist,	  the	  
complex	   mechanism	   of	   Ang2	   physiology	   remains	   somewhat	  
unknown	   (Maisonpierre	   et	   al.	   1997;	   Eklund	   and	   Saharinen	   2013).	  
Ang2	  is	  not	  crucial	  for	  embryogenesis,	  as	  seemingly	  normal	  mice	  are	  
born	   with	   Ang2-­‐knockout	   background.	   However,	   the	   mice	   lacking	  
Ang2	  soon	  develop	  severe	  chylous	  ascites	  and	  die	  postnatally.	  Ang2	  
is	   normally	   stored	   in	   the	   Weibel-­‐Palade	   bodies	   of	   EC	   with	  
endothelin-­‐1	   (ET-­‐1)	   and	   von	   Willebrand	   factor	   and	   IL-­‐8,	   and	   is	  
exocytosed	   upon	   stress,	   i.e.,	   in	   ischemia,	   shear	   stress,	   and	   VEGF.	  
Hypoxia	   induced	   RhoA	   activation	   and	   cytoskeletal	   changes	   have	  
essential	  role	  in	  Weibel-­‐Palade	  body	  exocytosis.	  (Vischer	  et	  al.	  2000;	  
Fiedler	   et	   al.	   2004;	   Kuo	   et	   al.	   2008).	   Recent	   studies	   have	   further	  
shed	   light	   on	   Ang2	   secretion	   by	   showing	   that	   Ang2	   is	   released	   in	  
exosomes	  when	  PI3K	  and	  Akt	  are	  inhibited,	  and	  that	  the	  release	  was	  
regulated	  by	  syndecan/syntenin	  pathway.	  (Tsigkos	  et	  al.	  2006;	  Ju	  et	  
al.	  2014)	  Ang2	  selectively	  competes	  with	  Ang1	  in	  binding	  to	  the	  Tie2	  
receptor	   and	   is	   considered	   to	   have	   antagonistic	   function	   on	   the	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receptor	  signaling	  in	  resting	  endothelium	  (Maisonpierre	  et	  al.	  1997).	  
However,	  exogenous	  and	  endogenous	  Ang2	  has	  been	  demonstrated	  
to	   induce	  Tie2	  phosphorylation	  under	  certain	  conditions	  (Kim	  et	  al.	  
2000;	   Daly	   et	   al.	   2006).	   Ang2	   has,	   therefore,	   context	   dependent	  
function	  and	  can	  enhance	  neovascularization,	  promote	  EC	  survival,	  
or	  increase	  vascular	  permeability	  (Oliner	  et	  al.	  2004;	  Nag	  et	  al.	  2005;	  
Gallagher	  et	  al.	  2007).	  	  
	  
Ang2	   expression	   increases	   in	   peripheral	   blood	   in	   several	   types	   of	  
malignancies.	   Its	  role	   in	  tumor	  environment	  has	  been	  suggested	  to	  
be	   closely	   linked	   to	   neovascularization,	   tumor	   growth	   and	  
metastasizing.	   (Etoh	   et	   al.	   2001;	   Scholz	   et	   al.	   2007;	   Schulz	   et	   al.	  
2011)	   Furthermore,	   increased	   expression	   of	   Ang2	   has	   been	  
associated	  with	  primary	  graft	  failure	  in	  lung	  transplant	  patients	  and	  
cardiac	   allograft	   vasculopathy	   development	   (Diamond	   et	   al.	   2012;	  
Daly	   et	   al.	   2013).	   The	   inflammatory	   function	   of	   Ang2	   partly	  
manifests	   as	   sensitization	   of	   endothelial	   cells	   to	   TNF-­‐a	   and	   by	  
increase	  of	  endothelial	  adhesion	  molecules	  (Fiedler	  et	  al.	  2006).	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AIMS	  OF	  THE	  STUDY	  
	  
The	  aim	  of	  this	  study	  was	  to	  characterize	  the	  effects	  of	  hypothermic	  
preservation	  on	  ischemia-­‐reperfusion	  injury	  and	  innate	  and	  adaptive	  
immune	   responses	   in	   rat	   cardiac	   allografts,	   and	   to	   investigate	   the	  
therapeutic	   effects	  of	   targeting	   the	  angiopoietin-­‐1	   and	   -­‐2	   signaling	  
with	  clinically	  relevant	  protein	  and	  antibody	  treatment	  in	  this	  animal	  
model.	  
	  
The	  specific	  aims	  of	  were:	  
1.	  	   to	   describe	   the	   effects	   of	   hypothermic	   preservation	   on	  
ischemia-­‐reperfusion	   injury	   and	   innate	   and	   adaptive	   immune	  
responses,	   and	   on	   the	   development	   of	   cardiac	   fibrosis	   and	  
allograft	  vasculopathy;	  
2.	   to	   investigate	   the	   effect	   of	   donor	   heart	   treatment	   with	  
recombinant	   and	   stable	   variant	   of	   native	   angiopoietin-­‐1	   on	  
ischemia-­‐reperfusion	   injury	   and	   subsequent	   development	   of	  
innate	  and	  adaptive	  immune	  responses	  in	  cardiac	  allografts;	  
3.	   to	   investigate	   the	   kinetics	   and	   mechanisms	   of	   angiopoeitin-­‐2	  
during	   ischemia-­‐reperfusion	   injury	   and	   adaptive	   immune	  




1.	  Experimental	  rat	  cardiac	  transplantation	  model	  
Specific	   pathogen-­‐free,	   inbred	   Dark	   Agouti	   (DA,	   RT1av1)	   rats	  
weighing	   200-­‐250	   g	   were	   used	   as	   cardiac	   allograft	   donors.	   The	  
donor	  rat	  heart	  was	  perfused	  with	   ice-­‐cold	  heparinized	  phosphate-­‐
buffered	   saline	   (PBS),	   and	   excised.	   In	   the	   treatment	   studies,	   the	  
coronaries	   were	   then	   perfused	   with	   200	   µl	   of	   anti-­‐Ang2	   antibody	  
(MEDI3617;	   150	   ng/ml,	   in	   PBS;	   MedImmune),	   or	   non-­‐specific	   IgG	  
(150	   ng/ml,	   in	   PBS;	   MedImmune),	   or	   with	   recombinant	   Ang2	   (50	  
µg/ml,	  in	  PBS)(Hwang	  et	  al.	  2005),	  COMP-­‐Ang1	  (10	  µg/ml,	  in	  PBS)	  or	  
PBS.	  The	  donor	  heart	  was	  preserved	   in	  PBS	  at	  4°C	   	   (cold	   ischemia)	  
for	  2	  to	  4	  h,	  depending	  on	  the	  study	  model	  (Tuuminen	  et	  al.	  2011).	  
Warm	   ischemia	   was	   standardized	   to	   1	   h.	   After	   preservation,	  
heterotopic	  cardiac	  transplantations	  were	  performed	  between	  fully	  
MHC-­‐mismatched,	  pathogen-­‐free,	  inbred	  8-­‐	  to	  12-­‐week-­‐old	  male	  DA	  
donor	   and	   Wistar	   Furth	   (WF,	   RT1u)	   recipient	   rats	   (Harlan	  
Laboratories,	  Boxmeer,	  The	  Netherlands).	  
	  
To	   prevent	   irreversible	   episodes	   of	   acute	   allograft	   rejection,	   to	  
achieve	  long-­‐term	  allograft	  survival,	  and	  to	  enable	  the	  development	  
of	   chronic	   rejection,	   the	   recipients	   in	   chronic	   rejection	   groups	  
received	   cyclosporine	  A	   (Novartis,	   Basel,	   Switzerland)	   2	  mg/kg/day	  
s.c.	   for	   the	   first	  7	  days	  and	  1	  mg/kg/day	  thereafter.	  For	  anesthesia	  
and	   perioperative	   analgesia,	   the	   recipient	   rats	   inhaled	   isoflurane	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(Isofluran,	   Baxter,	   Deerfield,	   IL)	   and	   received	   s.c.	   buprenorphine	  
(Temgesic,	  Schering-­‐Plough,	  Kenilworth,	  NJ).	  
	  
The	   effect	   of	   cold	   preservation	   on	   the	   integrity	   of	   microvascular	  
endothelial	  cells	  was	  analyzed	  by	  transmission	  electron	  microscopy	  
in	   the	   non-­‐transplanted	   DA	   donor	   hearts.	   After	   reperfusion,	   the	  
recipients	  of	  cardiac	  allografts	  were	  sacrificed	  at	  30	  min	  to	  analyze	  
the	   effect	   on	   microvascular	   perfusion	   and	   permeability	   with	  
Lycopersicon	   esculentum	   (Tomato)	   lectin	   perfusion	   and	   modified	  
Miles	   assay,	   at	   6	   h	   to	   analyze	   endothelial	   activation	   and	  
inflammatory	   cell	   influx	   with	   immunohistochemistry,	   myocardial	  
injury	   with	   serum	   troponin	   T	   (TnT)	   analysis,	   and	   innate	   immune	  
activation	  with	  real-­‐time	  quantitative	  reverse-­‐transcription	  PCR,	  and	  
at	   8	   weeks	   to	   analyze	   the	   degree	   of	   cardiac	   fibrosis	   and	   allograft	  
vasculopathy	  with	  histological	  stainings.	  
	  
The	  State	  Provincial	  Office	  of	  Southern	  Finland	  approved	  all	  animal	  
experiments.	   The	   animals	   received	   care	   in	   compliance	   with	   the	  
Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals	  as	  outlined	  by	  the	  
National	  Academy	  of	  Sciences	  (ISBN	  0-­‐309-­‐05377,	  revised	  1996).	  	  
	  
2.	  Transmission	  electron	  microscopy	  analysis	  
The	   mid-­‐cardiac	   specimens	   were	   fixed	   in	   2.5%	   glutaraldehyde	   in	  
phosphate	   buffer	   (pH	   7.4).	   The	   Advanced	   Microscopy	   Unit	  
(Haartman	   Institute,	   University	   of	   Helsinki,	   Helsinki,	   Finland)	  
prepared	   the	   samples	   by	   TEM-­‐routine:	   samples	  were	   post-­‐fixed	   in	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1%	   osmium	   tetroxide,	   then	   dehydrated	   in	   graded	   ethanol,	   and	  
embedded	   in	   Epoxy	   resin	   LX-­‐112.	   Ultra-­‐thin	   sections	   were	   cut	   at	  
around	  80	  nm.	  Electron	  staining	  was	  performed	  with	  uranyl	  acetate	  
and	   lead	   citrate	   in	   Leica	  EM	  STAIN	  automatic	   stainer.	   The	   sections	  
were	  then	  examined	  with	  JEM-­‐1400	  TEM	  (JEOL,	  Tokyo,	  Japan)	  at	  80	  
KV	   and	   analyzed	   the	   incidence	   of	   endothelial	   cell	   (EC)-­‐EC	   junction	  
gaps	  and	  EC	  blebbing	  with	  25000x	  magnification.	  
	  
3.	  Immunohistochemistry	  and	  immunofluorescence	  stainings	  
Cryostat	  sections	  were	  stained	  for	  subsets	  of	  inflammatory	  cells	  and	  
microvascular	  vessels	  using	  the	  peroxidase	  ABC	  method	  (Vectastain	  
Elite	  ABC	  Kit,	  Vector	  Laboratories)	  and	  the	  reaction	  was	  developed	  
with	   3-­‐amino-­‐9-­‐ethylcarbazole	   (AEC,	   Vectastain).	  
Immunofluorescent	   stainings	  were	   performed	   using	   Alexa	   568	   red	  
and	  Alexa	  488	  green	  (Promega,	  Madison,	  WI)	  secondary	  antibodies.	  	  
	  
The	   following	   antibodies	   and	   dilutions	  were	   used:	   Ang2	   (10μg/ml,	  
AF623,	   R&D	   Systems);	   RECA-­‐1	   for	   rat	   endothelium	   (50	   μg/ml,	  
MCA97,	   AbD	   Serotec,	   Dusseldorf,	   Germany);	   FLAG	   for	   COMP-­‐Ang1	  
(10μg/ml,	  Sigma-­‐Aldrich	  Co,	  St.	  Louis,	  MO);	  CD4	  for	  T	  cells	  (5	  µg/ml,	  
22021D,	   BD	  Pharmingen,	   San	  Diego,	   CA),	   CD8	   for	   T	   cells	   (5	   µg/ml,	  
22071D	   BD	   Pharmingen),	   ED1	   for	  macrophages	   (5	   µg/ml,	   22451D,	  
BD	   Pharmingen);	  MPO	   for	   neutrophils	   (20	   µg/ml,	   ab9535,	   Abcam,	  
Cambridge,	   UK);	   OX62	   for	   dendritic	   cells	   (10	   µg/ml,	   MCA	   1029G,	  
Serotec,	   Oxford,	   UK);	   VCAM-­‐1	   (10	   μg/ml,	   MMS-­‐141P,	   Covance,	  
Princeton,	   	  NJ);	   ICAM-­‐1	   (10	  μg/ml,	  1A29,	  Seikagaku,	  Tokyo,	   Japan).	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The	   immunoreactivity	   was	   quantified	   in	   a	   blinded	   manner	   using	  
400x	  magnification.	  
	  
4.	  Histological	  evaluation	  
Paraformaldehyde-­‐fixed	   paraffin	   mid-­‐cardiac	   cross	   sections	   were	  
used	   for	   histological	   stainings.	   The	   degree	   of	   cardiac	   fibrosis	   was	  
determined	   from	   cross	   sections	   subjected	   to	   Masson’s	   trichrome	  
staining	   and	   computer-­‐assisted	   image	   processing	   (Zeiss	   Axiovision	  
4.4,	  Munich,	  Germany)	  by	  measuring	  the	  average	  proportional	  area	  
stained	   for	   fibrosis	   from	   photographs	   captured	   with	   100x	  
magnification.	   Cardiac	   allograft	   vasculopathy	   was	   evaluated	   from	  
cross	  sections	  stained	  with	  hematoxylin-­‐eosin,	  and	  Resorcin-­‐Fuchsin	  
for	   internal	   elastic	   lamina,	   by	   measuring	   the	   area	   between	   the	  
internal	   elastic	   lamina	   and	   vessel	   lumen.	   The	   ratio	   of	   neointimal	  
area	   to	   internal	   elastic	   lamina	   determined	   the	   arterial	   occlusion	  
percentage.	  
	  
5.	  Enzyme-­‐linked	  immunosorbent	  assay	  
To	   quantify	   Ang1	   and	   Ang2	   from	   human	   and	   rat	   serum	   samples,	  
ELISA	  was	   performed	   according	   to	   the	  Manufacturer’s	   instructions	  
with	   following	   kits:	   human	   Ang1	   (DANG10;	   R&D	   Systems	   Inc.,	  
Minneapolis,	  MN);	  human	  Ang2	   (DANG20;	  R&D	  Systems);	   rat	  Ang2	  
(E90009Ra;	  Uscn	  Life	  Science	  Inc.,	  Wuhan,	  China).	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6.	  Cell	  culture	  assays	  
Human	   dermal	   blood	   microvascular	   endothelial	   cells	   (BECs)	  
(PromoCell,	  Heidelberg,	  Germany)	  were	  maintained	  on	  fibronectin-­‐
coated	   dishes	   in	   Endothelial	   Cell	   Basal	   Medium	   MV	   (ECBM,	  
PromoCell)	  with	  growth	  supplements	  provided	  by	  the	  manufacturer	  
and	  used	  in	  passages	  2-­‐6.	  Hypoxic	  treatment	  (1%	  O2)	  was	  carried	  out	  
in	  Invivo2	  400	  hypoxia	  chamber	  (Ruskinn	  Technology,	  Bridgend,	  UK).	  
Tie2-­‐GFP	   retroviral	   transfected	   cells	   were	   produced	   as	  
described(Saharinen	   et	   al.	   2008).	   Cells	   were	   treated	   with	   non-­‐
specific	   IgG	  (2	  mg/ml;	  MedImmune,	  Gaithesburg,	  MD)	  or	  anti-­‐Ang2	  
antibodies	  (MEDI3617;	  2	  mg/ml;	  MedImmune)	  or	  with	  COMP-­‐Ang1	  
(Cho	  et	  al.	  2004)	  (50	  ng/ml).	  The	  cells	  were	  fixed,	  permeabilized,	  and	  
stained	  for	  Ang2,	  Tie2,	  or	  COMP-­‐Ang1.	  
	  
7.	  Microvascular	  leakage	  and	  perfusion	  assay	  
A	   modified	   Miles	   assay	   was	   used	   to	   measure	   extravasation	   of	  
plasma	  proteins	  from	  the	  microvasculature	  into	  the	  interstitial	  space	  
of	   cardiac	   allografts:	   immediately	   after	   reperfusion,	   the	   recipients	  
were	   injected	   i.v.	   with	   Evans	   Blue	   dye	   (Sigma-­‐Aldrich;	   30	   mg/ml	  
diluted	   in	  0.9	  %	  NaCl),	  and	  allowed	   this	   to	  circulate	   for	  30	  min.	  To	  
detect	  perfused	  vessels	  30	  min	  after	  reperfusion,	  50	  ml	  FITC-­‐labeled	  
Lycopersicon	   esculentum	   (Tomato)	   lectin	   (Vector	   Laboratories,	  
Burlingame,	  CA)	  diluted	  in	  150	  ml	  of	  0.9%	  NaCl	  was	  injected	  to	  the	  
aortic	   root	   a	   few	   minutes	   before	   removing	   the	   allografts.	  
Immediately	   thereafter,	   the	   right	   auricle	   was	   incised	   and	   the	  
coronary	  network	  was	  flushed	  with	  5	  ml	  of	  1	  %	  PFA	  in	  0.05	  M	  citrate	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buffer,	  pH	  3.5.	  For	  quantification	  of	  extravasated	  Evans	  Blue,	  100	  mg	  
of	  apical	  myocardium	  was	  incubated	  into	  500	  ml	  of	  formamide	  on	  a	  
shaker	  at	  +60	   °C	   for	  24	  h.	   The	  absorbance	  of	  dissolved	  Evans	  Blue	  
dye	  was	  then	  measured	  from	  the	  formamide	  by	  spectrophotometry	  
at	   610	   nm	   wavelength.	   The	   mean	   density	   of	   FITC	   positive	  
microvascular	   vessels	  was	   quantified	   from	  mid-­‐axial	   cross	   sections	  
from	  10	  random	  fields	  of	  each	  cardiac	  cross	  section	  by	  fluorescence	  
microscopy.	  
	  
8.	  Gene	  expression	  analysis	  
Total	   RNA	   was	   isolated	   from	   tissue	   samples	   dissected	   from	   the	  
myocardial	  midpiece	  of	  the	  allografts	  using	  RNeasy	  kit	  according	  to	  
the	   Manufacturer’s	   instructions	   (Qiagen,	   Hilden,	   Germany)	   and	  
reverse	   transcribed	   by	   using	   the	   High-­‐RNA-­‐to-­‐cDNA	   kit	   (Applied	  
Biosystems,	   Foster	   City,	   CA).	   Quantitative	   real-­‐time	   PCR	   was	  
performed	   on	   a	   RotorGene-­‐6000	   (Corbett	   Research,	   Doncaster,	  
Australia)	   using	   2X	   DyNAmo	   Flash	   SYBR	   Green	   Master	   mix	  
(Finnzymes,	   Espoo,	   Finland)	   and	   the	   mRNA	   quantities	   of	   the	  
following	   factors	  were	  measured	   from	  each	  group:	   innate	   immune	  
receptors	   TLR2	   and	   TLR4,	   their	   ligands	   biglycan,	   HAS1-­‐3,	   HMGB1,	  
transcription	   factor	   NF-­‐kB,	   dendritic	   cell	   (DC)	   maturation	   markers	  
CD80,	  CD86,	  and	  CD83,	  as	  well	  as	  inflammatory	  cytokines	  TNF-­‐a,	  IL-­‐
1b,	  IP-­‐10,	  TGF-­‐b,	  IL-­‐6	  and	  IL-­‐10.	  The	  number	  of	  mRNA	  copies	  of	  the	  
gene	  of	  interest	  was	  calculated	  from	  a	  corresponding	  standard	  curve	  
using	   the	   RotorGene	   software.	   Of	   the	   tested	   housekeeping	   genes	  
(18SRNA,	   GAPDH,	   b-­‐actin	   and	   TBP),	   18SRNA	   was	   most	   stably	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expressed	   and	   therefore	   all	   RT-­‐PCR	   data	   were	   normalized	   against	  
18SRNA.	  
	  
9.	  Heart	  transplant	  patients	  
The	   data	   consists	   of	   11	   cardiac	   allograft	   donors	   (8	   men)	   and	   11	  
recipients	   (8	   men)	   operated	   between	   2010	   and	   2011	   in	   Helsinki	  
University	   Central	   Hospital,	   Helsinki,	   Finland.	   Healthy	   volunteers	  
were	  used	  as	  a	  control	  group	  (n	  =	  24;	  9	  men).	  The	  mean	  age	  of	  the	  
donors	   was	   40.9±14.1	   years	   (range	   19-­‐56	   years),	   of	   the	   recipients	  
47.4±11.4	  years	   (range	  29-­‐63	  years),	  and	  of	   the	  healthy	  volunteers	  
34.9±11.9	   years	   (range	   22-­‐61).	   Blood	   samples	   were	   collected	  
preoperatively	   from	   cardiac	   allograft	   donors	   and	   postoperatively	  
from	   the	   recipients	   1,	   6,	   and	   24	   h	   after	   transplantation	   and	   ELISA	  
was	  used	  to	  measure	  the	  serum	  levels	  of	  Ang1	  and	  Ang2.	  The	  Ethical	  
Committee	  of	  University	  of	  Helsinki,	  Helsinki,	  Finland	  approved	  the	  
use	  of	  the	  patient	  samples,	  and	  each	  patient	  gave	  written	  informed	  
consent.	  	  
	  
10.	  Statistical	  analysis	  
All	   data	   are	   two	   group	   comparisons	   were	   performed	   by	   Mann-­‐
Whitney	   U	   test;	   multiple	   group	   comparisons	   were	   performed	   by	  
Kruskal-­‐Wallis	   analysis	   with	   Dunn	   correction,	   or	   by	   repeated	  
measures	  ANOVA	  using	  PASW	  Statistics	  19.0	  (SPSS	  Inc.,	  Chicago,	  IL).	  
P<0.05	  was	  considered	  statistically	  significant.	  




1. Prolonged ischemic preservation promoted ischemia-
reperfusion injury-mediated myocardial injury and inflammation 
in rat cardiac allografts (I) 
Myocardium	   is	   highly	   susceptible	   to	   hypoxic	   injury.	   Cardiomyocyte	  
injury	   is	   therefore	   inevitable	   during	   organ	   recovery	   and	  
preservation.	   Prolonged	   ischemic	   time	   resulted	   in	   profound	  
myocardial	  injury,	  but	  also	  increased	  the	  influx	  of	  inflammatory	  cells	  
into	   the	   allograft.	   The	   acute	   Tx-­‐IRI	   phase	   was	   characterized	   by	  
increased	   expression	   of	   innate	   immune	   activating	   endogenous	  
danger	   molecules	   and	   influx	   of	   innate	   immune	   macrophages	   and	  
neutrophils	  alongside	  with	  induction	  of	  inflammatory	  cytokines	  IFN-­‐
γ,	  IL-­‐6,	  and	  TNF-­‐α.	  
	  
2. Prolonged ischemic preservation enhanced chronic rejection 
(I) 
As	   regards	   alloimmune	   activation,	   allografts	   transplanted	   after	  
prolonged	  ischemic	  preservation	  exhibited	  increased	  influx	  of	  CD4+	  
and	   CD8+	   T	   cells,	   as	   well	   as	   macrophages,	   10	   days	   after	   the	  
transplantation	   and	   under	   subclinical	   immunosuppression.	  
Interestingly,	   during	   Th1-­‐inhibiting	   CsA	   immunosuppression,	  
prolonged	  preoperative	  ischemic	  preservation	  resulted	  in	  shifting	  of	  
the	   cytokine	   profile	   of	   allograft-­‐infiltrating	   T	   cells	   towards	   Th17	  
alloimmune	  response.	  This	  was	  seen	  as	  increased	  IL-­‐17	  and	  IL-­‐23p19	  
gene	  expression.	  Paradoxically,	  Treg-­‐associated	  FoxP3	   transcription	  
factor	   expression	   was	   also	   robustly	   induced	   during	   alloimmune	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response.	   Increased	   myocardial	   injury,	   acute	   and	   sustained	  
inflammation	   reflected	   as	   accelerated	   the	   development	   of	   cardiac	  
fibrosis,	   loss	   of	   functional	   capillary	   network,	   and	   arterial	   luminal	  
occlusion.	  
	  
These	   findings	   emphasize	   the	   importance	   of	   early	   allograft	   injury	  
and	   inflammation	   in	   the	   development	   of	   late	   dysfunction,	   and	  
suggests	   early	   protection	   of	   allografts	   as	   potential	   target	   for	  
treatment	  with	  long-­‐lasting	  effects.	  
	  
3. Hypoxia induced endothelial cells to release Ang2 
(unpublished) 
Previous	  findings	  indicate	  that	  hypoxia	  regulates	  Ang2	  expression	  in	  
human	  umbilical	  vein	  endothelial	  cells	  (Pichiule	  et	  al.	  2004).	  Human	  
blood	   microvascular	   endothelial	   cells	   were	   incubated	   in	   hypoxic	  
environment	   for	   1,	   3,	   8,	   12,	   or	   24	   hours,	   and	   the	   culture	  medium	  
was	   analyzed	   for	   Ang2	   with	   ELISA.	   In	   congruence	   with	   previous	  
findings,	   the	   data	   showed	   2-­‐fold	   increase	   in	   Ang2	   secretion	   in	  
response	  to	  hypoxia	  during	  24-­‐hour	   incubation,	  when	  compared	  to	  








When	   Tie2-­‐overexpressing	   ECs	   were	   incubated	   in	   hypoxia,	   the	  
secreted	   Ang2	   localized	   into	   EC-­‐EC	   junctions	   and	   associated	   with	  
Tie2.	   Application	   of	   anti-­‐Ang2	   antibody	   blocked	   this	   Ang2/Tie2	   co-­‐
localization	   (Figure	   9A).	   Similarly,	   exogenous	   Ang1	   applied	   to	   the	  
culture	  localized	  with	  Tie2	  receptor	  in	  normoxia,	  but	  to	  lesser	  extent	  
during	   hypoxia	   indicating	   competitive	   binding	   to	   Tie2	   with	   Ang2	  
(Figure	  10	  B-­‐C).	  
	  























Figure	   10.	  Hypoxia	   induces	   Ang2	   deposition	   in	   endothelial	   cell-­‐cell	  
junctions	   and	   inhibits	   Ang1-­‐Tie2	   binding	   in	   endothelial	   cells.	   A,	  
Human	   dermal	   blood	   microvascular	   cells	   (BECs)	   transfected	   with	  
Tie2-­‐GFP	  retrovirus	  were	  subjected	  to	  normoxia	  or	  hypoxia	  (1%	  O2)	  
for	   16	   h	   in	   the	   presence	   of	   control-­‐IgG	   or	   anti-­‐Ang2	   antibody	   (2	  
μg/ml).	   Immunofluorecent	   staining	   shows	   the	   localization	   of	   Tie2	  
(green)	   and	   Ang2	   (red);	   DAPI	   indicates	   nuclei	   (blue).	   B,	   Tie2-­‐GFP	  
retrovirus	   transfected	   BECs	   were	   cultured	   in	   normoxia	   or	   hypoxia	  
(1%	  O2)	  for	  24	  h,	  and	  stimulated	  with	  COMP-­‐Ang1-­‐FLAG	  (50	  ng/ml)	  
for	   the	   last	   30	  min.	  C,	   fractional	  area	  of	   Tie2/FLAG	  double-­‐positive	  
pixels	   from	   total	   area	   quantified	   from	   samples	   incubated	   in	  
normoxia	   and	   hypoxia	   with	   or	   without	   COMP-­‐Ang1.	  
Immunofluorecent	   staining	   shows	   the	   localization	   of	   Tie2	   (green)	  
and	  COMP-­‐Ang1	  (FLAG;	  red).	  DAPI	  indicates	  nuclei	  (blue).	  Scale	  bars	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4. Cardiac transplantation induces immediate changes in 
angiogenic growth factor expression in human and in rat (III) 
Heart	   transplant	   donors	   and	   recipients	   were	   analyzed	   for	   serum	  
levels	  of	  Ang1	  and	  Ang2	  before	  organ	  donation	  and	  during	  the	  first	  
24	   h	   after	   the	   transplantation.	   No	   changes	   were	   observed	   in	   the	  
serum	  levels	  of	  Ang1	   in	  the	  donors	   (Figure	  11A).	  The	  expression	  of	  
Ang2	  was	  increased	  in	  brain	  dead	  heart	  donors	  compared	  to	  healthy	  
volunteers	   (Figure	   11B).	   In	   the	   recipient	   patients,	   heart	  
transplantation	   induced	   progressive	   decrease	   in	   Ang1	   levels	   and	  
increase	   Ang2	   expression	   during	   the	   first	   24	   h	   (Figure	   11C,D).	  
Similarly,	   in	   experimental	   rat	   cardiac	   transplantation,	   allogeneic	  
heart	   transplantation	   resulted	   in	   serum	   release	   of	   Ang2,	   but	  
interestingly	   reduced	   expression	   of	   Ang1	   in	   peripheral	   blood.	  
Syngeneic	   transplant	   recipients,	   however,	   showed	   no	   changes	   in	  
serum	  levels	  of	  Ang2.	  













Figure	  11.	  Peripheral	  blood	  analysis	  for	  Ang1	  and	  2	  levels	  in	  cardiac	  
allograft	  donors	  after	  brain	  death	  and	  in	  cardiac	  allograft	  recipients	  
after	   transplantation.	   A	   and	   B,	   Human	   plasma	   samples	   from	  
hemodynamically	   stable	  cardiac	  allograft	  donors	   (D;	  n	  =	  19)	  before	  
organ	  procurement	  and	  compared	  to	  healthy	  controls	  (CTRL;	  n	  =	  24)	  
analyzed	  by	   enzyme-­‐linked	   immunosorbent	   assay	   (ELISA).	  C	  and	  D,	  
Human	   plasma	   samples	   form	   cardiac	   allograft	   recipients	   (n=19)	  
before	   transplantation	   (0	   h)	   and	   6,	   and	   24	   h	   after	   transplantation	  
analyzed	  by	  ELISA.	  Data	  are	  given	  as	  scatter	  plot	  where	  the	  black	  bar	  
indicates	  mean.	  ***P<0.001	  by	  Repeated	  ANOVA	  measurements.	  
	  
	  
5. Targeting Ang/Tie2 pathway prevented Tie2-dependent 
endothelial destabilization and microvascular dysfunction 
induced by ischemic preservation (II-III) 
Rat	   heart	   procurement	   and	   hypothermic	   preservation	   resulted	   in	  
endothelial	   destabilization,	   morphological	   changes	   in	   EC,	   and	  
disruption	   of	   EC-­‐EC	   connections	   observed	   with	   transmission	  
electron	   microscopy	   analysis.	   When	   the	   allografts	   were	   ex	   vivo	  
perfused	  either	  with	  recombinant	  Ang1	  or	  with	  anti-­‐Ang2	  antibody,	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Allograft	  tissue	  perfusion	  was	  measured	  from	  the	  apex	  of	  the	  heart	  
with	   laser	   Doppler	   velocimetry	   immediately	   after	   reperfusion.	   Ex	  
vivo	   donor	   heart	   treatment	   either	   with	   COMP-­‐Ang1	   or	   with	   anti-­‐
Ang2	   antibody	   resulted	   in	   significantly	   improved	  myocardial	   tissue	  
perfusion	   during	   the	   first	   10	  minutes	   after	   reperfusion.	   This	   effect	  
was	   dependent	   on	   functional	   capillaries,	   as	   the	   histologically	  
determined	   numbers	   of	   perfused	   vessels	   were	   increased	   30	   min	  
after	  the	  reperfusion	  in	  the	  treatment	  groups,	  whereas	  the	  absolute	  
numbers	  of	  vessels	  were	  indifferent.	  	  
	  
Endothelial	   stability	  was	   further	  assessed	  by	  microvascular	   leakage	  
in	   modified	   Miles	   assay,	   in	   which	   the	   recipient	   is	   perfused	   with	  
albumin-­‐binding	  Evans	  Blue	  dye,	  and	  the	  extravasation	  of	  the	  dye	  is	  
assessed	  30	  min	  after	  the	  reperfusion.	  Both	  donor	  heart-­‐targeted	  ex	  
vivo	   COMP-­‐Ang1	   and	   anti-­‐Ang2	   antibody	   treatment	   stabilized	   the	  
allograft	   endothelium	   and	   preserved	   functional	   capillary	   network,	  
whereas	   Tx-­‐IRI	   in	   control	   allografts	   resulted	   in	   reduced	   capillary	  
density	  and	  increased	  Evans	  Blue	  extravasation.	  
	  
Ex	   vivo	   donor	   heart	   treatment	   with	   COMP-­‐Ang1	   or	   anti-­‐Ang2	  
antibody	   prevented	   such	   early	   inflammatory	   response	   by	   reducing	  
the	  influx	  of	   inflammatory	  cells	  as	  well	  as	  downregulating	  the	  gene	  
expression	   of	   TLR-­‐activating	   ligands.	   Importantly,	   these	   findings	  
were	   associated	   with	   significantly	   lower	   immunoreactivity	   of	  
endothelial	  adhesion	  molecules	  ICAM-­‐1	  and	  VCAM-­‐1.	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6. Acute rejection can be restrained by endothelial inactivation 
(III) 
Alloimmune	   response	   is	   imminent	   after	   allogeneic	   solid	   organ	  
transplantation.	  Prolonged	  preoperative	  ischemia	  prior	  to	  allogeneic	  
cardiac	  transplantation,	  however,	  worsens	  the	  acute	  innate	  immune	  
response	   in	   the	  absence	  of	   immunosuppressive	  medication.	   In	  our	  
experimental	   model,	   the	   fully	   MHC-­‐mismatched	   cardiac	   allografts	  
are	   rejected	   in	   5	   or	   6	   days,	   if	   the	   recipients	   are	   not	  
immunosuppressed.	  When	   daily	   administration	   of	   CsA	   1mg/kg	   i.p.	  
was	  applied,	  the	  allograft	  survival	  extended	  to	  10-­‐15	  days.	  Recipient	  
treatment	  with	   single-­‐dose	  of	  anti-­‐Ang2	  antibody	   failed	   to	  prolong	  
allograft	   survival	   with	   this	   background	   immunosuppression.	  
However,	  when	  the	  administration	  was	  continued	  on	  days	  1,	  3,	  and	  
5	   after	   the	   transplantation,	   the	   survival	   was	   highly	   significantly	  
prolonged	  (Figure	  12).	  















Figure	   12.	   The	   effect	   of	   systemic	   recipient	   anti-­‐Ang2	   antibody	  
treatment	  on	  rat	  cardiac	  allograft	  survival.	  Red	  dash	  line	  represents	  
the	   survival	   of	   allografts	   transplanted	   after	   4-­‐h	   hypothermic	  
preservation	   and	   without	   any	   immunosuppression.	   Red	   line	  
represents	   allograft	   survival	   in	   recipients	   treated	   CsA	   1	  mg/kg	   s.c.	  
and	  with	  non-­‐specific	   IgG	   i.p.	   4h	  before	   the	   transplantation.	  Green	  
line	   represents	   allograft	   survival	   in	   recipients	   treated	   CsA	   1	  mg/kg	  
s.c.	  and	  with	  anti-­‐Ang2	  antibody	   i.p.	  4h	  before	  the	  transplantation.	  
Blue	   line	   represents	   allograft	   survival	   in	   recipients	   treated	   CsA	   1	  
mg/kg	  s.c.	  and	  with	  anti-­‐Ang2	  antibody	   i.p.	  4h	  before,	  and	  on	  days	  
1,	  3,	  and	  5	  after	  the	  transplantation.	  Data	  are	  presented	  by	  Kaplan-­‐
Meier	  survival	  plot.	  ***P<0.001	  by	  Log	  Rank	  analysis.	  
	  
	  
7. Cardiac allograft vasculopathy development is correlated 
with preoperative ischemia time and the number of endothelial 
cells and pericytes (I-III) 
Cardiac	   allograft	   vasculopathy	   was	   associated	  with	   gradual	   loss	   of	  
rat	   endothelial	   cell	   antigen-­‐1	   (RECA-­‐1)	   positive	   capillaries,	   but	   also	  
NG2-­‐positive	   pericytes.	   Donor	   heart	   treatment	   with	   COMP-­‐Ang1	  
inhibited	   early	   endothelial	   activation,	   but	   also	   preserved	   the	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Figure	  13.	  The	  density	  of	  RECA-­‐1+	  EC	  (A)	  and	  NG2+	  pericytes	   (B)	   in	  
COMP-­‐Ang1-­‐	   and	   PBS-­‐treated	   allografts	   at	   6	   h,	   10	   d,	   56	   d.	  
Representative	   immunofluorescence	   images	   from	   different	  
timepoints	   (C).	   Scale	  bar	  =	  40	  µm.	  Data	  are	  given	  as	  mean	  ±	  SEM.	  
*P<0.05,	  **P<0.01	  by	  the	  Mann-­‐Whitney	  U	  test.	  
	  
	  
Ischemic	   time	   in	   clinical	   cardiac	   transplantation	   is	   an	   independent	  
risk	   factor	   for	   cardiac	   allograft	   vasculopathy	   development.	   In	   a	  
chronic	  rejection	  model,	  rat	  cardiac	  allografts	  were	  transplanted	  to	  
recipient	   rats	   receiving	   subclinical	   immunosuppression	   to	   prevent	  
episodes	  of	  acute	  rejection.	  This	  treatment	  protocol	  enabled	  chronic	  
rejection	   associated	   arterial	   luminal	   occlusion	   and	   myocardial	  
fibrosis	   development	   in	   2-­‐month	   follow-­‐up.	   Cardiac	   allograft	  
vasculopathy	   changes	   were	   correlated	   with	   allograft	   preoperative	  
ischemic	  time	  (Figure	  14).	  
























































































Figure	   14.	   Cardiac	   allograft	   vasculopathy	   analyzed	   56	   d	   after	   rat	  
allogeneic	   heart	   transplantation.	   A,	   B,	   and	   C,	   the	   incidence,	  
occlusion,	  and	  representative	  histological	   images	  of	  arterial	   luminal	  
occlusion	   in	   allografts	   transplanted	   after	   0,	   2,	   or	   4	   h	   hypothermic	  
preservation.	   D	   and	   E,	   myocardial	   fibrosis	   analyzed	   semi-­‐
quantitatively	  from	  Masson-­‐Trichrome	  stainings.	  Scale	  bar	  =	  40	  µm.	  
Data	  are	  given	  as	  mean	  ±	  SEM.	  *P<0.05,	  **P<0.01,	  ***P<0.001	  by	  




Donor	  heart	  ex	  vivo	  treatment	  either	  with	  recombinant	  COMP-­‐Ang1	  
protein,	   or	   with	   anti-­‐Ang2	   antibody	   significantly	   inhibited	   the	  
development	   of	   aforementioned	   chronic	   rejection-­‐associated	  
changes.	  Systemic	  recipient	  treatment	  with	  anti-­‐Ang2	  antibody	  had	  
similar	   effects	   on	   allograft	   vasculopathy	   development,	   indicating	  
that	  early	  inflammation	  is	  crucial.	  
	  
	   	  
 69 
DISCUSSION	  
Solid	   organ	   transplantation	   can	   be	   regarded	   as	   one	   of	   the	   crown	  
achievements	   of	  modern	   surgery.	   Replacing	   failing	   livers,	   lungs,	   or	  
hearts	  with	   functional	   grafts	   from	  brain	   dead	   donors	   gives	   second	  
chance	  to	  those	  patients	  with	  otherwise	  virtually	  no	  hope	  for	  living.	  
The	  median	   survival	   of	   heart	   transplant	   recipients	   has	   exceeded	   a	  
decade	  many	  years	  ago,	  and	  it	  keeps	  prolonging	  (Stehlik	  et	  al.	  2012).	  
Primary	  graft	  dysfunction	  and	  allograft	   vasculopathy	  are	   important	  
factors	   limiting	   short-­‐	   and	   long-­‐term	   survival	   of	   cardiac	   transplant	  
recipients.	   This	   study	   emphasizes	   the	   role	   of	   hypothermic	  
preservation,	   and	   moreover,	   IRI	   as	   an	   inductor	   of	   microvascular	  
dysfunction,	  and	  innate	  and	  adaptive	  immune	  responses	  leading	  to	  
primary	  and	  late	  allograft	  dysfunction	  after	  cardiac	  transplantation.	  
The	  results	  presented	  here	  shed	   light	  on	  the	  characteristics	  behind	  
IRI-­‐induced	  inflammation	  and	  allograft	  dysfunction,	  and	  their	  impact	  
on	   the	   development	   of	   cardiac	   fibrosis	   and	   allograft	   vasculopathy.	  
Tie2	   signaling	   was	   proven	   important,	   as	   supplementation	   of	  
recombinant	   Tie2	   agonist	   COMP-­‐Ang1	   or	   inhibition	   of	   Tie2	  
antagonist	   Ang2	   with	   specific	   antibody	   resulted	   in	   significant	  
improvement	   in	   microvascular	   function	   and	   allograft	   survival,	   as	  
well	  as	  inhibition	  of	  innate	  and	  adaptive	  immune	  responses	  and	  the	  
development	  of	  cardiac	  fibrosis	  and	  allograft	  vasculopathy.	  
	  
Donor	  aspects	  and	  preservation	  
Incredible	   success	   of	   clinical	   heart	   transplantation	   has	   with	  
increasing	  numbers	  of	  heart	  transplant	  recipient	  candidates	  resulted	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in	   chronic	   shortage	   of	   donated	   organs.	   This	   shortage	   has	   required	  
extending	  the	  donor	  pool	   to	  marginal,	  or	  extended	  criteria	  donors,	  
who	   are	   older	   and	   sicker	   than	   previously	   accepted.	   Furthermore,	  
the	   brain	   death	   of	   organ	   donor	   may	   induce	   a	   release	   of	  
catecholamines,	   a	   systemic	   inflammatory	   response,	   microvascular	  
endothelial	   cell	   and	   pericyte	   dysfunction,	   and	   myocardial	   injury	  
(Venkateswaran	   et	   al.	   2009).	   Both	   longer	   ischemic	   time	   and	  
increased	   donor	   age	   are	   independent	   risk	   factors	   for	   1-­‐year	  
mortality	  after	  the	  transplantation	  (Lund	  et	  al.	  2013).	  
	  
Grafts	  from	  donors	  with	  extended	  criteria	  are	  especially	  susceptible	  
to	   primary	   graft	   dysfunction	   and	   injury	   requiring	   novel	   treatment	  
strategies	   to	   prevent	   Tx-­‐IRI-­‐induced	   effects	   (Iyer	   et	   al.	   2011;	  
Abecassis	   et	   al.	   2012).	   An	   experimental	   rat	   study	   demonstrated	  
worse	  cardiac	   function	   in	  grafts	   from	  older	  donor	   rats	  during	  early	  
reperfusion	   phase	   compared	   to	   grafts	   from	   younger	   donors	  
(Korkmaz	  et	  al.	  2013).	  Recipients	  with	  grafts	   from	  marginal	  donors	  
have	   higher	   risk	   for	   primary	   graft	   failure	   and	   require	   temporary	  
circulatory	  support	  with	   i.e.	  extracorporeal	  membrane	  oxygenation	  
(Listijono	   et	   al.	   2011).	   The	   use	   of	   temporary	   circulatory	   support,	  
however,	  is	  again	  a	  significant	  risk	  factor	  for	  1-­‐	  and	  5-­‐year	  mortality	  
(Lund	  et	  al.	  2013).	  
	  
Current	   clinical	   organ	   preservation	   protocols	   abrogate	   Tx-­‐IRI	   only	  
partially.	  With	  current	  immunosuppressive	  regimen,	  the	  episodes	  of	  
acute	   rejection	   are	   preventable,	   but	   chronic	   rejection	   still	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significantly	  limits	  the	  survival	  of	  cardiac	  allograft	  recipients	  (Lund	  et	  
al.	   2013).	   According	   to	   2012	   ISHLT	   Registry	   data,	  median	   ischemic	  
time	  for	  cardiac	  transplant	  is	  3.1	  hours.	  At	  the	  same	  time,	  ischemic	  
time	  exceeding	  200	  minutes	  is	  an	  independent	  risk	  factor	  for	  cardiac	  
allograft	  vasculopathy	  development.	  (Stehlik	  et	  al.	  2012)	  
	  
The	  problems	  with	  donors	  with	  extended	  criteria	  and	  ischemic	  time	  
may	  be	  manageable	  with	  novel	  preservation	   techniques,	   solutions,	  
or	   treatment	   options.	   Ex	   vivo	   heart	   perfusion	   machines	   are	   long	  
studied	   with	   little	   progression	   regarding	   the	   heart	   (Jacobs	   et	   al.	  
2010).	   However,	   Organ	   Care	   System	   for	   ex	   vivo	   perfusion	   of	   lung	  
allografts	   has	   shown	   promising	   potential	   and	   is	   currently	   further	  
investigated	   (Warnecke	   et	   al.	   2012).	   Novel	   preservation	   solutions	  
are	   investigated	   in	   order	   to	   preserve	   grafts	   longer	   and	   in	   warmer	  
temperatures	   (Thatte	  et	   al.	   2009;	   Lowalekar	  et	   al.	   2013).	   Similarly,	  
solution	   with	   small	   interfering	   RNA	   against	   proinflammatory	  
cytokines	   and	   complement	   has	   proven	   potential	   in	   prolonged	  
allograft	  preservation	  (Zheng	  et	  al.	  2009).	  	  
	  
Reperfusion	  phase	  
Ischemia	   is	  not	  the	  sole	  determining	  factor	   for	  myocardial	   injury	   in	  
Tx-­‐IRI,	  as	  syngeneic	  rat	  cardiac	  transplants	  with	  similar	  preoperative	  
ischemic	  time	  exhibit	  significantly	  milder	  cardiomyocyte	  injury	  than	  
allogeneic	  transplants	  (Keränen	  et	  al.	  2013).	  Allorecognition	  initiates	  
after	   allogeneic	   solid	   organ	   transplantation	   regardless	   of	   T	   cell-­‐
targeted	   immunosuppression.	   The	   duration	   of	   hypothermic	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preservation,	   however,	   dictates	   the	   intensity	   of	   innate	   immune	  
response	  after	  reperfusion	  of	  the	  allograft	  (I).	  
	  
Tx-­‐IRI	   is	   an	   inevitable	   factor	   in	   solid	   organ	   transplantation,	   but	  
differs	   greatly	   from	   conventional	   IRI	   occurring	   in	   the	   treatment	   of	  
stroke	  or	  acute	  coronary	  syndrome.	  Rapid	  neutrophilic	  infiltration	  is	  
resolved	  in	  24	  h	  in	  syngrafts,	  whereas	  infiltrating	  CD8+	  T	  cells	  induce	  
sustained	   neutrophilic	   influx	   to	   allografts	   (El-­‐Sawy	   et	   al.	   2004).	  
Furthermore,	  hypothermic	  preservation	  of	  cardiac	  allografts	  during	  
organ	   recovery	   and	   transportation	   induces	   ischemic	   injury	   to	  
cardiomyocytes,	   but	   also	   inflicts	   endothelial	   cell	   and	   pericyte	  
detachment	  from	  one	  another	  and	  disruption	  of	  endothelial	  barrier	  
(Tuuminen	   et	   al.	   2011).	   Longer	   preservation	   promotes	   endothelial	  
and	   pericyte	   dysfunction	   that	   manifests	   as	   myocardial	   capillary	  
perfusion	   defect,	   microvascular	   leakage,	   vasoconstriction,	   and	   EC	  
activation.	  Activated	  EC	  increase	  adhesion	  molecule	  expression	  and	  
EC-­‐EC	   junction	   disruption	   allows	   easier	   transmigration	   of	  
inflammatory	   cells.	   Together	   with	   increased	   accumulation	   of	  
inflammatory	   cells	   and	   secreted	   proinflammatory	   cytokines,	  
perfusion	   defect	   induces	   significantly	   worse	   cardiomyocyte	   injury	  
after	  prolonged	  preservation.	  (II-­‐III)	  
	  
Immunological	  issues	  
Foreign	   tissue	   transplanted	   to	   allogeneic	   recipient	   is,	   without	  
immunosuppression,	   rapidly	   rejected	   by	   innate	   immune	   cells	   such	  
and	   NK	   cells	   and	   adaptive	   immune	   response	   involving	   antigen-­‐
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presenting	   cells	   and	   the	   generation	   of	   allograft-­‐specific	   IFN-­‐γ	  
producing	  Th1-­‐type	  T	   cells	   (Lehmann	  et	   al.	   1997).	   Endothelial	   cells	  
are	  extremely	  important	  in	  the	  course	  of	  immunological	  recognition,	  
inflammatory	  cell	  recruitment,	  and	  myocardial	  perfusion.	  EC	  express	  
both	   MHC	   class	   I	   and	   class	   II	   molecules	   on	   their	   cytoplasmic	  
surfaces,	  and	  therefore,	  can	  communicate	  with	  both	  CD4+	  and	  CD8+	  
T	  cells	  and	  induce	  IL-­‐2	  production.	  EC	  have,	  however,	  been	  shown	  to	  
stimulate	   only	   memory,	   but	   not	   naïve	   CD8+	   T	   cells	   to	   become	  
cytolytic	   T	   cells.	   (Hancock	   et	   al.	   1982)	   Activated	   EC	   may	   drive	  
sustained	   inflammation	  behind	  allograft	   rejection	  by	   inducing	   local	  
IFN-­‐γ	   secretion	  by	   T	   cells	   (Salomon	  et	   al.	   1991;	   Tellides	   and	  Pober	  
2007).	  Type	  I	  activation	  of	  EC	  is	  gene	  transcription-­‐independent	  and	  
results	  from	  histamine	  or	  thrombin,	  and	  manifests	  as	  nitric	  oxide	  or	  
prostaglandin	  secretion,	  or	  Weibel	  Palade	  body	  exocytosis,	  resulting	  
in	   vasodilatation,	   increased	   perfusion,	   and	   permeability	   disorder.	  
Type	   II	  activation	   is	  described	  as	   transcription-­‐dependent	  adhesion	  
molecule	  upregulation	  induced	  by	  cytokines	  such	  as	  TNF-­‐α,	  and	  IL-­‐1	  
(Pober	  and	  Sessa	  2007).	  Activated	  EC	  promote	   leukocyte	  activation	  
and	   transmigration	   by	   secretin	   cytokines	   and	   chemokines,	   i.e.	  
PECAM-­‐1,	  IL-­‐8,	  IP-­‐10,	  MCP-­‐1,	  and	  RANTES	  (Al-­‐Lamki	  et	  al.	  2008).	  
	  
Endothelium	   is	   the	   physiological	   first	   line	   barrier	   and	   defence	  
between	  circulating	  inflammatory	  cells	  and	  the	  allograft.	  Therefore,	  
injury	   to	   EC	   greatly	   contributes	   to	   cardiac	   allograft	   vasculopathy	  
development.	   In	   allogeneic	   environment,	   macrophages,	   cytotoxic	  
CD8+	  T	  cells	  and	  natural	  killer	  cells	   induce	  EC	  apoptosis	  by	  non-­‐self	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recognition,	   Bax-­‐induction,	   death	   receptor-­‐signaling,	   or	   by	   TNF-­‐
related	   apoptosis-­‐inducing	   ligand	   (Zheng	   et	   al.	   2000;	   Hsieh	   et	   al.	  
2002;	   Bleackley	   2005;	   Wyburn	   et	   al.	   2005).	   EC	   are,	   however,	  
resistant	  to	  injury	  and	  apoptosis	  by	  upregulating	  anti-­‐apoptotic	  zinc	  
finger	   protein	   A20,	   heme	   oxygenase-­‐1,	   Bcl-­‐2,	   or	   the	   PI3k/Akt	  
pathway.	  (Soares	  et	  al.	  1999;	  Madge	  and	  Pober	  2000)	  
	  
Our	  findings	  suggest	  that	  early	  EC	  activation	  may	  be	  a	  key	  mediator	  
of	  chronic	   inflammation,	  and	  that	  preventing	  this	  activation	  results	  
as	  significant	  improvement	  in	  allograft	  function	  and	  survival.	  (II-­‐III)	  
	  
Cardiac	  allograft	  vasculopathy	  and	  late	  graft	  dysfunction	  
The	   early	   innate	   immune	   response	   following	   solid	   organ	  
transplantation	   is	   described	   by	   infiltration	   of	   inflammatory	   cells	  
consisting	   mainly	   of	   macrophages,	   neutrophils	   and	   NK	   cells	  
depending	   on	   cellular	   adhesion	   molecules	   (El-­‐Sawy	   et	   al.	   2004;	  
2005).	   Dendritic	   cells	   and	   macrophages	   rapidly	   recognize	   foreign,	  
allogeneic	  antigens,	  but	  also	  allograft-­‐derived	  TLR-­‐activating	  danger	  
molecules	   result	   in	   innate	   and	   alloimmune	   activation	   (Goldstein	  
2004).	   Immunosuppressive	  drugs	  mainly	  target	   IL-­‐2-­‐mediated	  T	  cell	  
activation	   and	   proliferation;	   corticosteroids	   also	   inhibit	   but	   fail	   to	  
completely	   prevent	   innate	   immune	   activation.	   Of	   inflammatory	  
cytokines,	  IL-­‐6	  is	  extremely	  important	  in	  early	  CD4+	  T	  cell	  mediated	  
inflammation	   and	   allograft	   rejection.	   	   In	   allogeneic	  murine	   cardiac	  
transplant	   model,	   recipient	   anti-­‐IL-­‐6	   antibody	   treatment	   results	   in	  
prolonged	  survival	  (Lei	  et	  al.	  2010).	  In	  a	  similar	  experimental	  setting,	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but	  with	   recipient	  mice	  depleted	  of	  CD8+,	   IL-­‐6	   inhibition	   results	   in	  
virtually	   non-­‐existent	   rejection,	   even	  when	   administered	   6	   d	   after	  
transplantation	  (Booth	  et	  al.	  2011).	  	  
	  
The	  answer	  to	  the	  pathophysiology	  of	  cardiac	  allograft	  vasculopathy	  
remains	  yet	  to	  be	  fully	  elucidated.	  On	  the	  cellular	  level,	  T	  cell	  driven	  
alloimmune	   response	   may	   be	   considered	   the	   main	   driving	   force	  
behind	   allograft	   vasculopathy	   development.	   Accelerated	   Th17	  
alloimmune	   response	   results	   in	   allograft	   rejection	   in	   Th1-­‐deficient	  
mice	   (Yuan	   et	   al.	   2008),	   and	   also	   seemed	   to	   promote	   chronic	  
rejection	  development	  in	  our	  experimental	  model	  (I).	  Different	  T	  cell	  
depletion	   strategies	   are	   used	   in	   clinical	   practice	   mainly	   as	   an	  
induction	   therapy	   in	  kidney	   transplantation,	  but	   to	   lesser	  extent	   in	  
other	   organs.	   Rapid	   release	   of	   cytokines,	   opportunistic	   infections,	  
lymphoproliferative	   diseases,	   and	   T	   cell	   repopulation	   are	   most	  
common	   problems,	   and	   despite	   of	   effectively	   promoting	  
immunosuppression	  early	  after	  transplantation,	  T	  cell	  depletion	  fails	  
to	  induce	  tolerance	  (Page	  et	  al.	  2013).	  
	  
As	  described	  above,	  EC	  have	  high	  potential	  in	  inducing	  or	  regulating	  
inflammatory	  responses	  after	  allogeneic	  solid	  organ	  transplantation.	  
Based	   on	   results	   presented	   in	   papers	   II	   and	   III,	   endothelial	  
stabilization	   and	   inactivation	   are	   crucial	   for	   allograft	   survival	   and	  
evasion	  from	  rejection.	  With	  inactivated	  endothelium,	  the	  need	  for	  
T	  cell	  depletion-­‐mediated	  induction	  therapy	  may	  reduce.	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Angiopoietins	  in	  solid	  organ	  transplantation	  
Angiogenic	   growth	   factors	   are	   intensively	   studied	   in	   the	   field	   of	  
cancer	   science,	   as	   angiogenesis	   is	   crucial	   for	   tumor	   growth	   and	  
metastasis	   (Welti	   et	   al.	   2013).	   Interestingly,	   the	   same	   factors	   that	  
promote	   tumor	   growth	   elicit	   vascular	   instability	   in	   solid	   organ	  
transplantation.	  	  
	  
Endothelial	  detachment	  is	  essential	  for	  neovascularization	  and	  VEGF	  
is	  a	  potent	  angiogenic	  growth	   factor	   inducing	   rapid	  and	  prominent	  
vascular	   leakage	   (Nagy	   et	   al.	   2012).	   VEGF	   activates	   EC	   in	  
transplantation	   setting,	   and	   neutralization	   of	   VEGF	   has	   anti-­‐
inflammatory	  effect	  in	  cardiac	  allografts	  by	  inhibiting	  the	  expression	  
of	  endothelial	  cell	  adhesion	  molecules	  and	  the	  production	  of	  several	  
chemokines	  (Lemström	  et	  al.	  2002;	  Reinders	  et	  al.	  2003).These	  VEGF	  
mediated	   pro-­‐inflammatory	   effects	   are	   possibly	   downstream	   of	  
Ang2	   signaling,	   and	   preventable	   by	   Ang2	   inhibition	   (III).	   Another	  
study	   shows	   that	   neutralization	   of	   Ang2	   reduces	   endothelial	  
adhesion	   molecule	   expression	   in	   murine	   ischemic	   limb	   model	  
(Tressel	   et	   al.	   2008).	   Rat	   cardiac	   allograft	   treatment	   ex	   vivo	   with	  
anti-­‐Ang2	  antibody	  reduces	  VEGF	  and	  TGF-­‐b	  mRNA	  expression	  after	  
the	  transplantation	  and	  subsequently	   inhibits	  vascular	  permeability	  
and	  perfusion	  disorder,	  and	  fibrosis	  development	  (III).	  
	  
Ang1	   elicits	   vascular	   stability	   and	   homeostasis	   during	   normal	  
physiology.	   Ang1	   signaling	   through	   Tie2	   receptor	   promotes	   anti-­‐
apoptotic	   signals	   particularly	   by	   activating	   PI3k/Akt	   pathway	   and	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ABIN	   (Papapetropoulos	   et	   al.	   2000;	   Tadros	   et	   al.	   2003).	  
Furthermore,	  type	  I	  endothelial	  activation	  may	  be	  avoided	  by	  Ang1,	  
which	   prevents	  VEGF-­‐induced	  plasma	   leakage	   and	   enhances	   EC-­‐EC	  
connections	   at	   cell	   junctions.	   Ang1	   also	   reinforces	   blood	   vessel	  
coating	  by	  pericytes	  and	  surrounding	  extracellular	  matrix.	  (Thurston	  
et	   al.	   2000;	   Saharinen	   et	   al.	   2008)	   Donor	   heart-­‐targeted	   Ang1	  
treatment	   stabilized	   microvascular	   endothelium	   of	   the	   allografts	  
and	  inhibited	  innate	  and	  alloimmune	  responses	  (II).	  Maintaining	  EC	  




A.	  Donor	  perspective	  
Currently,	   transplant	  units	  suffer	   from	  chronic	  shortage	  of	  donated	  
organs.	   Recognizing	   potential	   organ	   donors	   is	   a	   key	   factor	   in	  
increasing	   the	  numbers	  of	   solid	  organ	   transplants.	   In	  addition,	  due	  
to	   the	   shortage	   of	   organ	   donors,	   older	   and	   sicker	   patients	   are	  
accepted	   as	   organ	   donors.	   This	   makes	   donor	   management	  
important	   issue.	   Brain	   death	   of	   heart	   transplant	   donors	   causes	  
systemic	   cytokine	   storm.	   Circulating	   inflammatory	   cytokines	   may	  
prime	   the	   heart	   for	   subsequent	   inflammation	   and	   injury.	   Current	  
clinical	  protocols	  include	  donor	  treatment	  with	  systemic	  steroids	  to	  
prevent	   the	   adverse	   effects	   of	   this	   cytokine	   storm,	   but	   more	  
targeted	   treatment	   may	   be	   advantageous.	   Donor	   preoperative	  
simvastatin	   treatment	   in	   experimental	   rat	   cardiac	   transplantation	  
model	  protects	  the	  allograft	  from	  post-­‐operative	  problems,	  such	  as	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Tx-­‐IRI	   and	   chronic	   rejection	   development	   (Tuuminen	   et	   al.	   2011).	  
Our	   studies	   have	   pointed	   Ang2	   to	   be	   increased	   in	   the	   donor	  
peripheral	   blood	   before	   organ	   procurement,	   and	   therefore	   a	  
potential	  target	  for	  donor	  treatment.	  
	  
B.	  Allograft	  (preservation)	  perspective	  
The	   allograft	   is	   subjected	   to	   hypothermia	   and	   ischemia	   during	   the	  
preservation.	  Organ	  preservation	   solutions	  are	  designed	   to	  protect	  
the	  allograft	   from	  adverse	  effects	  of	  hypoxia,	  acidosis,	   low	  glucose	  
levels,	   and	   edema	   (Jacobs	   et	   al.	   2010).	   Antioxidants	   are	   included	  
also	   in	   some.	   Potential	   treatment	   targets	   are	   the	   oxygen	  
metabolism	   producing	   reactive	   oxygen	   species	   during	   ischemic	  
preservation,	  endothelial	  protection	  and	  inactivation,	  or	  prevention	  
of	  allorecognition.	  Solution	  with	  small	   interfering	  RNA	  against	  TNF-­‐
α,	  C3,	  and	  Fas	  has	  shown	  promising	  potential	  in	  prolonged	  allograft	  
preservation	  (Zheng	  et	  al.	  2009).	  Also,	  novel	  preservation	  solutions	  
are	   designed	   to	   enable	   the	   allografts	   to	   be	   preserved	   in	   milder	  
hypothermia,	  or	  even	  normothermia	  (Thatte	  et	  al.	  2009;	  Lowalekar	  
et	   al.	   2013).	   Restoration	  of	   circulation	  with	   perfusion	   system	  after	  
allograft	  recovery	  has	  been	  studied	  for	  decades,	  however,	  the	  costs	  
and	   perfusion	   system	   management	   issues	   have	   resulted	   this	  
technique	   to	   be	   concluded	   as	   inferior	   to	   static	   hypothermic	  





C.	  Recipient	  perspective	  
Current	   immunosuppressive	   protocols	  mostly	   target	   IL-­‐2-­‐mediated	  
adaptive	  immunity.	  Novel	  immunomodulatory	  strategies	  that	  target	  
anything	   else	   may	   reduce	   the	   need	   for	   classical	  
immunosuppressants.	   Recipient	   treatment	   with	   statins	   has	   long	  
been	   standard	   treatment	   for	   their	   anti-­‐inflammatory	   properties	  
(Kobashigawa	   et	   al.	   1995;	   Shimizu	   et	   al.	   2003).	   Angiopoietins	   play	  
crucial	   role	   in	  maintaining	  EC	  quiescence.	  The	  endothelium	  acts	  as	  
the	  definitive	  barrier	  between	  the	   transplant	  and	  the	  effector	  cells	  
of	   alloimmune	   system,	   and	   therefore	   it	  may	   be	   hypothesized	   that	  
the	   alloimmune	   response	   may	   be	   absent	   if	   the	   endothelium	   is	  
preserved	  intact	  and	  non-­‐adhesive	  to	  inflammatory	  cells.	  Our	  results	  
show	   that	   Ang1	   substitution	   or	   Ang2	   neutralization	   inhibit	   early	  
influx	   of	   inflammatory	   cells,	   and	   also	   the	   early	   alloimmune	  
response,	  as	  the	  gene	  expression	  of	  hallmark	  cytokines	  IL-­‐2,	  IL-­‐6,	  IL-­‐
12	   were	   downregulated.	   Ang1	   has	   therefore	   potential	   in	   allograft	  
protection	   during	   the	   preservation.	   Ang2	   competes	   with	   Ang1	   in	  
binding	   to	   the	   Tie2	   receptor,	   promotes	   inflammation	   and	  
endothelial	   activation,	   and	   acts	   as	   a	   chemokine	   to	   inflammatory	  
cells.	  Neutralization	  of	  Ang2	  may	  therefore	  be	  beneficial	  during	  the	  








The	  experimental	  rat	  cardiac	  allograft	  model	  used	   in	  this	  study	   is	  a	  
non-­‐functional	   and	   heterotopic	   model.	   Therefore,	   the	   model	  
represents	   clinical	   cardiac	   transplantation	   mainly	   immunologically.	  
The	   model	   excludes	   donor	   brain	   death,	   which	   produces	   systemic	  
cytokine	  storm	  and	  induces	  early	  innate	  immune	  response	  in	  clinical	  
patients.	  The	  treatment	  agents	  used	  in	  this	  study	  are	  not	  in	  clinical	  
use,	  but	  are	  currently	  in	  clinical	  trials.	  
	  
Conclusions	  
This	   study	  emphasizes	   the	   importance	  of	   ischemia	  and	  reperfusion	  
on	   endothelial	   integrity	   in	   cardiac	   allografts.	   With	   functional	   and	  
intact	   endothelium,	   the	   key	   mediators	   of	   inflammation	   and	  
alloimmune	  response	  are	  unable	  to	  reach	  the	  allograft.	  This	  results	  
in	   delayed	   allorecognition	   and	   subsequently	   reduced	   development	  
of	  cardiac	  allograft	  vasculopathy.	  Angiopoietin	  signaling	  was	  proven	  
important	  in	  endothelial	  stabilization,	  either	  by	  supplementation	  of	  
Ang1	   or	   inhibition	   of	   Ang2.	   Further	   studies	   are	   warranted	   to	  
investigate	   the	   clinical	   potential	   of	   Ang1	   and	   inhibition	   of	   Ang2	   in	  
human	   solid	   organ	   transplant	   recipients.	   In	   human	   patients,	  
recombinant	  Ang1	  may	  be	  added	  to	  cardioplegia	  solutions	  and	  anti-­‐
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YHTEENVETO	  	  
Elinsiirrettä	   irrotettaessa	   verenkierto	   katkaistaan	   ja	   elin	  
jäähdytetään	   kudosvaurion	   minimoimiseksi.	   Verenkierron	  
palauttaminen	   siirteeseen	   aiheuttaa	   paradoksaalisesti	   iskemia-­‐
reperfuusiovaurioksi	   kutsutun	   ilmiön,	   johon	   liittyy	   verisuoniston	  
seinämän	  aktivoituminen	  ja	  synnynnäisen	  immuniteetin	  aiheuttama	  
neutrofiili-­‐	  ja	  makrofagivaltainen	  tulehdusreaktio.	  Tämä	  alkuvaiheen	  
tulehdusreaktio	   altistaa	   elinsiirteen	   myöhäisvaiheen	   krooniselle	  
tulehdusreaktiolle,	   jonka	   vuoksi	   siirteen	   toiminta	   voi	   pettää.	   Sydän	  
on	   erityisen	   herkkä	   hapenpuutteelle,	   minkä	   vuoksi	   sydänsiirteen	  
iskemia-­‐aika	   pyritään	   pitämään	   mahdollisimman	   lyhyenä.	  
Pidentynyt	   iskemia-­‐aika	   –	   sairaaloidenvälisen	   pitkän	   matkan	   tai	  
teknisesti	   vaikean	   leikkauksen	   vuoksi	   –	   on	   itsenäinen	   riskitekijä	  
myöhään	  kehittyvälle	  hyljintäreaktiolle.	  
	  
Angiopoietiini-­‐1	   ja	   -­‐2	   (Ang1	   ja	   2)	   ovat	   Tie2-­‐reseptoriin	   sitoutuvia	  
verisuonikasvutekijöitä,	   joilla	   on	   tärkeä	   merkitys	  
verenkiertoelimistön	   sikiöaikaisessa	   kehityksessä.	   Verisuonten	  
tukisolut	   erittää	   jatkuvasti	   Ang1:tä,	   joka	   ylläpitää	   verisuonen	  
seinämän	   tasapainoa	   kehittyneessä	   verisuonistossa.	   Ang2	  
puolestaan	   vapautuu	   verisuonen	   seinämän	   endoteelisoluista	  
hapenpuutteen	   tai	   tulehduksen	   vaikutuksesta	   ja	   houkuttelee	  




Tässä	   tutkimuksessa	   kuvattiin	   koe-­‐eläinmallilla	   sydänsiirteen	  
kylmäsäilytyksen	   vaikutus	   luonnollisen	   immuniteetin	  
aktivoitumiseen	   ja	   kroonisen	   hyljintäreaktion	   kehittymiseen.	  
Tutkimuksessa	   selvitettiin	   myös	   Ang1-­‐	   ja	   Ang2-­‐signalointiteiden	  
vahvistamisen	   tai	   estämisen	   vaikutusta	   sydänsiirteen	   iskemia-­‐
reperfuusiovaurioon	   ja	   hyljintäreaktion	   kehittymiseen.	   Pidentynyt	  
kylmäsäilytys	  lisäsi	  tulehdusvastetta	  ja	  huononsi	  siirteen	  ennustetta.	  
Tutkimuksessa	   havaittiin,	   että	   Ang2	   vapautuminen	   verenkiertoon	  
lisääntyy	   sydänsiirteen	   saaneella	   potilaalla	   1.	   vuorokauden	   aikana	  
leikkauksen	   jälkeen.	   Sama	   ilmiö	   osoitettiin	   myös	   rotan	  
sydänsiirtomallissa	   ja	   samalla	   todettiin	   tulehdusreaktion	   olevan	  
hapenpuutetta	  merkittävämpi	  Ang2	  vapauttaja.	  
	  
Tutkimuksessa	   rotan	   sydänsiirtomallissa	   siirteen	   sepelvaltimoihin	  
irrotuksen	   yhteydessä	   ruiskutettu	   Ang1-­‐proteiini	   stabiloi	   siirteen	  
verisuoniston	   seinämän	   ja	   Ang2-­‐vasta-­‐aine	   esti	   iskemia-­‐
reperfuusiovaurioon	  liittyvän	  tulehduksen	  ja	  sydänlihasvaurion,	  sekä	  
hiussuoniston	   läpäisevyys-­‐	   ja	   perfuusiohäiriön.	   Tämä	   alkuvaiheen	  
suojavaikutus	  hillitsi	  myös	  siirteiden	  kroonisen	  hyljinnän	  muutoksien	  
kehittymistä.	   Sydänsiirteen	   vastaanottajalle	   systeemisesti	   annettu	  
vasta-­‐aine	   ei	   vaikuttanut	   verisuoniston	   läpäisevyyteen,	   mutta	   esti	  
siirteen	   tulehduksen,	   akuutin	   hyljintäreaktion	   ja	   kroonisen	  
hyljintäreaktion	  kehittymisen.	  
	  
Elinsiirtopotilaan	   ennustetta	   rajoittavat	   merkittävästi	   siirteen	  
varhaisvaiheen	  pettäminen	  ja	  kroonisen	  hyljintäreaktion	  aiheuttama	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hitaasti	   kehittyvä	   siirteen	   toiminnan	   hiipuminen.	   Tutkimuksen	  
tulosten	   perusteella	   Ang1-­‐signaloinnin	   vahvistaminen	   ja	   Ang2-­‐
signaloinnin	   vaimentaminen	   estää	   sydänsiirteen	   verisuoniston	  
seinämän	   endoteelisoluja	   aktivoitumasta,	   houkuttelemasta	   ja	  
läpäisemästä	   tulehdussoluja.	   Vasta-­‐ainehoidolle	   olisi	   kliinistä	  
käyttöä	   elinsiirtopotilaiden	   induktiohoidossa,	   jolloin	  
vaihtoehtoisella,	   elimistön	   immuunipuolustukseen	  
vaikuttamattomalla	   hoidolla	   voidaan	   vähentää	   potilaiden	  
tarvitsemien	   immunosuppressiivisten	   lääkkeiden	   määrää	   ja	   näin	  
ollen	  lääkkeistä	  aiheutuvia	  haittavaikutuksia.	  
	  
Tässä	   tutkimuksessa	   osoitettiin	   koe-­‐eläinmallissa,	   että	   estämällä	  
angiopoietiini-­‐2	   (Ang2)	   vaikutus	   vasta-­‐aineella	   paikallisesti	  
sydänsiirteessä	   tai	   siirteen	   vastaanottajassa	   vähennetään	   siirteen	  
varhaisvaiheen	   sydänlihasvauriota	   ja	   tulehdusvastetta.	  
Varhaisvaiheen	  hoidolla	  oli	  myös	  pitkäaikainen	  hyöty,	  sillä	  hoidetut	  
siirteet	   selvisivät	   pidempään	   ilman	   akuuttia	   ja	   kroonista	  
hyljintäreaktiota.	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